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1 Introduction 
1.1 Leukemia 
Cancer is one of the leading causes of death worldwide. In 2004 approximately   
13 % of all human deaths were due to cancer (WHO, 2009). Leukemia accounts 
for about 3.8 % of all cancer deaths (CD Mathers, 2001).  
Leukemia can be divided into lymphoid and myeloid leukemia. These expressions 
characterize the lineage the malignant cells originate from (SH Swerdlow, 2008).  
Furthermore, leukemic disorders can be divided into acute and chronic forms. 
Acute leukemia leads to death in as short a time as days or weeks, if untreated. 
This is caused by differentiation arrest, which leads subsequently to an excess of 
immature cells in the bone marrow, as well as in the peripheral blood. Chronic 
leukemia may lead to death within months or years. It is also characterized by an 
overbalance of one hematopoietic cell line. The cells however show a more 
mature differentiation (SH Swerdlow, 2008). 
In the following section I will briefly describe the main types of leukemia that are 
relevant to this study (AML, ALL, CML). 
 
1.1.1 Acute Lymphoblastic Leukemia (ALL) 
Acute Lymphoid Leukemia or Acute Lymphoblastic Leukemia is characterized by 
an excess of immature lymphocytes that may accumulate in the bone marrow and 
sometimes in the peripheral blood (RF Cornell, 2012). The disease is more 
common in children than in adults. The median age at diagnosis is 13 years, 
whereas the peak incidence is between the ages of 2 to 10 years. 80 % of 
childhood leukemia is diagnosed as ALL. The total incidence (all ages) is 
approximately 2/100.000/year (JF Yamamoto, 2008). ALL is considered as acute 
leukemia due to the relatively short course leading to death if untreated. The 
symptoms are related to the progression of bone marrow suppression or organ 
infiltration. If treated in time, the prognosis of ALL is generally positive with a cure 
rate of more than 80 %, however, in the case of relapse, the prognosis is rather 
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adverse. Genetic abnormalities are found to be important prognostic factors and 
should be taken into account, when diagnosing ALL (NL Harris, 2000).  Table 1.1 
demonstrates the relation of prognosis and cytogenetic alterations (RW McKenna, 
2000). 
 
Table 1.1: This table shows the correlation between cytogenetic features and the clinical prognosis. Adapted 
from RW McKenna, 2000.  
 
There are two main classifications for ALL. The former commonly used 
classification is the FAB (French-American-British) classification (see Table 1.2). It 
was first proposed in 1976 and is based on the phenotype of the leukemic cells. 
But the morphological categorization does not show prognostic relevance. On the 
other hand this classification is easy to use because no advanced technologies 
are needed (RW McKenna, 2000). 
 
Prognosis of ALL related to cytogenetics 
Favorable Hyperdiploidy >50 
 cryptic t(12;21)(p12;q22) 
Intermediate Hyperdiploidy 47-50 
 Normal (diploidy) 
 del(6q) 
Unfavorable Hypodiploidy: near haploid 
 near tetraploid 
 del17p 
 t(9;22)(q34;q11) 
 t(11q23), usually t(4;11) 
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Table 1.2: This table displays the classification criteria of the French-American-British Classification. They are 
based on morphologic and cytochemical features. Adapted from RW McKenna, 2000.  
 
Table 1.3: The table shows the classification of acute lymphoblastic leukemia by the World Health 
Organization. Adapted from NL Harris, 2000. 
 
The World Health Organization (WHO) developed a new classification in 2001 
(see table 1.3). It includes cytochemistry, immunophenotyping, genetics and 
clinical features, in addition to morphology (JW Vardiman, 2009). This ensures 
prognostic information and has a great impact on the determination of the 
appropriate treatment. 
FAB classification of ALL 
 L1 L2 L3 
Cell size Small Large, often heterogeneous 
Large, 
homogenous 
Amount of 
cytoplasm Scant 
Moderately 
abundant 
Moderately 
abundant 
Nucleoli Inconspicuous Prominent Present, may be prominent 
Cytoplasmatic 
vacuoles Variable Variable Prominent 
WHO classification of ALL 
Precursor B-cell acute lymphoblastic leukemia (cytogenetic 
subgroups) 
   t(9;22)(q34;q11) BCR/ABL 
   t(v;11q23) MLL rearranged 
   t(1;19)(q23;p13) E2A/PBX1 
   t(12;21)(p12;q22) ETV/CBFα 
Precursor T-cell acute lymphoblastic leukemia 
Burkitt cell leukemia 
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1.1.2 Acute Myeloid Leukemia (AML)  
Acute Myeloid Leukemia, also known as Acute Myelogenous Leukemia, is 
characterized by a clonal proliferation of myeloid precursors who have a reduced 
capacity to differentiate between e.g. granulocytes or monocytes. These immature 
leukemic blasts can accumulate in the bone marrow, peripheral blood and other 
organ tissues. This causes symptoms varying according to the infiltration (RF 
Cornell, 2012). 
AML is more common in adults. It accounts for about 80 % of acute leukemia in 
adults. The median age at diagnosis is 65 years. The incidence of AML increases 
with age, but the total incidence remains relatively stable at approximately 3-
5/100.000/year over the years. AML is slightly more common in men with a male: 
female ratio of 5:3 (JF Yamamoto, 2008). 
An important factor for the prognosis is cytogenetics. Table 1.4 displays the 
relationship between 5-year survival and cytogenetic abnormalities (K Wheatley, 
1999). 
 
Table 1.4: This table shows the correlation of certain cytogenetic alterations and their prognosis. Adapted from 
K Wheatley, 1999.  
 
The FAB classification of AML, as well as for ALL, is the most commonly used 
classification. This classification divides AML into eight subtypes (M0-M7) based 
mainly on morphological features of the leukemic cell (see Table 1.5; RW 
Risk 
Category 
Cytogenetic abnormality 5-year 
survival 
Favorable t(8;21), t(15;17), inv(16) 70 % 
Intermediate Normal, +8, +21,+22, del(7q), del(9q), Abnormal 
11q23, all other structural or numerical changes 
48 % 
Adverse -5, -7, del(5q), Abnormal 3q, Complex cytogenetics 15 % 
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McKenna, 2000). Though still frequently used, the WHO classification offers a 
more useful categorization due to its diagnostic, prognostic and therapeutic 
relevance (JW Vardiman, 2009). Table 1.6 gives an overview of the WHO 
classification. 
  
Table 1.5: Subgroups of AML characterized by the French-American-British Classification. Adapted from RW 
McKenna, 2000. 
 
 
FAB classification of AML 
M0 Myeloblastic leukemia minimally differentiated 
M1 Myeloblastic leukemia without maturation 
M2 Myeloblastic leukemia with maturation 
M3 
Hypergranular promyelocytic leukemia 
Microgranular variant 
M4 
Myelomonocytic leukemia 
With bone marrow eosinophilia (M4E0) 
M5 
Monocytic leukemia 
Poorly differentiated (M5A) 
Differentiated (M5B) 
M6 Erythroleukemia 
M7 Megakaryoblastic leukemia 
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Table 1.6: Classification of AML by the World Health Organization (WHO). Adapted from NL Harris, 2000. 
 
1.1.3 Chronic Myeloid Leukemia (CML) 
Chronic Myeloid Leukemia or Chronic Myelogenous Leukemia (CML) mostly 
presents with elevated white blood cell count with left shift, often with basopilia, 
and an enlarged spleen. Many patients display no symptoms or non-specific 
symptoms like malaise, fever or anemia on diagnosis (J Cortes, 2012;  
NF Grigoropoulos, 2013). CML can affect individuals at any age, although the 
majority is middle-aged or elderly on diagnosis. The incidence is 1-2/100.000/year 
with a slight predominance of men over women (JF Yamamoto, 2008). CML 
accounts for 20-30 % of all leukemia in adults. The course of the disease can be 
divided into three phases, starting with the chronic phase that may last for years. 
WHO Classification of AML 
I. AML with recurrent cytogenetic translocations 
AML with t(8;21)(q22;q22), AML1(CBFα)/ETO 
Acute promyelotic leukemia with t(15;17)(q22;21) and variants, PML/RARα 
AML with abnormal bone marrow eosinophils inv(16)(p13;q22) or 
t(16;16)(p13;q22), CBFβ/MYH11X 
AML with 11q23 (MLL) abnormalities 
II. AML with multilineage dysplasia 
With prior myelodysplastic syndrome 
Without prior myelodysplastic syndrome 
III. AML and myelodysplastic syndrome, therapy related 
Alkylating agent related 
Epipodophyllotoxin related 
Other types 
IV. AML not otherwise categorized 
AML minimally differentiated 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monocytic leukemia 
Acute erythroid leukemia 
Acute megakaryocytic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
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The disease continues to the acceleration phase and terminates with the blast 
crisis.  
 
Table 1.7: The WHO characterizes the acceleration phase of CML as displayed in this table. Adapted from  
JW Vardiman, 2002. 
 
Any of the characteristics mentioned in Table 1.7 may be an indicator for a 
progress of the disease to the acceleration phase. It is of great importance to 
recognize this development because, in this stage, a blast crisis is of a much 
higher risk. The blast crisis behaves similarly to acute leukemia and shows a rapid 
turnover of the cells. The progression can be diagnosed if any of the following is 
present: 
 
Table 1.8: The table displays the criteria to diagnose a blast crisis in patients with CML. Adapted from 
 JW Vardiman, 2002. 
 
Acceleration phase of CML 
10–19% blasts of peripheral blood cells or bone marrow cells 
>20% basophiles in the peripheral blood 
Persistent thrombocytopenia (<100 x 109/L) unrelated to therapy, or persistent 
thrombocytosis (>100 x 109/L) unresponsive to therapy 
Increasing spleen size and increasing WBC count unresponsive to therapy 
Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional 
genetic abnormality that was not present in the initial specimen at the time of 
diagnosis of chronic phase CML) 
Criteria for blast phase  
>20% blasts of peripheral blood cells or bone marrow cells 
Extramedullary blast proliferation 
Large foci or clusters of blasts in the bone marrow biopsy 
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1.2 Genetics and leukemia 
1.2.1 Basis of tumor genetics 
1.2.1.1 Tumor suppressor gene: 
Tumor suppressor genes are genes that have an influence on cell cycle control, 
e.g. inhibition of cell proliferation. More precisely, they encode for proteins that are 
involved in regulation of progression through certain stages of the cell cycle  
(e.g. Rb), checkpoint-control proteins that lead to cell cycle arrest, if the DNA is 
damaged (e.g. p53), proteins that promote apoptosis or DNA repair enzymes  
(H Lodish, 2007). If these genes are altered in their function, the cell cycle 
regulation is disturbed. This leads to uncontrolled proliferation, although the DNA 
is already damaged. Further mutations can accumulate under these conditions 
and contribute to the development of hematopoietic malignancy. This principle of 
oncogenesis is known as “Loss of Function” (WS Klug, 2005). 
The inactivation of a tumor suppressor gene can take place due to mutations, 
deletions, as well as inversions and translocations, which result in an inoperable 
gene (T Burmeister, 2000).  
Mostly it is not sufficient that only one allele is altered to cause malignant 
transformation. Knudson’s “Two-hit” hypothesis points out that both alleles of a 
tumor suppressor gene have to be inactivated to initiate tumor development  
(AG Knudson, 1971).  
TP53 is the most popular example of a tumor suppressor gene. 
 
1.2.1.2 Proto-oncogene: 
Proto-oncogenes usually have an important role in cell physiology. Genetic 
alterations can transform a proto-oncogene into an oncogene. A “gain of function” 
mutation is needed for this process (H Lodish, 2007). Such mutation could be 
amplification of a DNA segment that holds a proto-oncogene and subsequently 
leads to overexpression of the encoded gene. Alternatively, the proto-oncogene 
comes under the control of a different promoter or enhancer, which also leads to 
overexpression of the oncogene. Another possibility would be balanced 
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chromosomal translocations. A fusion gene can result from this translocation, 
which codes for a protein with an altered function. Here only one allele has to be 
affected to trigger malignant transformation (WS Krug et al., 2005). 
An example for the activation of a proto-oncogene will be given later in the chapter 
on chromosomal translocations. 
 
1.2.2 Chromosomal alteration 
Until now, more than 56,000 chromosomal alterations have been reported across 
all main cancer types (Mitelman Database of Chromosome Aberrations in Cancer, 
JD Rowley, 1999). However, there are a number of recurrent balanced 
chromosomal rearrangements, especially translocations. For some there is 
compelling evidence that they are strongly associated with distinct tumor entities. 
These aberrations occur more often in hematological disorders than in malignant 
solid tumors. In acute myeloid leukemia, for example, 1,785 balanced aberrations 
were identified, of which 267 are recurrent balanced abnormalities. Whereas in 
breast cancer, only 343 balanced abnormalities could be detected of which only 13 
are recurrent (F Mitelman, 2007). 
To date, in hematopoietic disorders, 264 fusion genes have been identified 
involving 238 different genes. This means that 75 % of all currently known gene 
fusions present in hematological malignancies (F Mitelman, 2007). 
Chromosomal alterations can be found by standard cytogenetic techniques in at 
least 70 to 80 % of leukemia cases on diagnosis (T Burmeister, 2000). These 
cytogenetic analyses provide diagnostic as well as prognostic information. In this 
way, these techniques become increasingly important for the clinical management 
of patients with hematological malignancies (B Johansson, 2004; I Panagopoulos, 
2006). 
  
1.2.3 Chromosomal translocations 
A chromosomal translocation is a chromosomal aberration and describes the 
rearrangement of parts of the genetic material between two or more non-
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homologous chromosomes (M Nambiar, 2008). This process may be balanced or 
unbalanced. A translocation is referred to as balanced if the amount of DNA 
remains unchanged after the translocation. In unbalanced translocations, the 
amount of genetic material is altered. That means either fragments of the DNA are 
lost or extra DNA fragments are added during the translation process (PD Aplan, 
2006). 
Two main types of chromosomal translocation are known: reciprocal  
(non- Robertsonian) and Robertsonian translocations. 
Chromosomal translocations are referred to as reciprocal when segments are 
exchanged between two non-homologous chromosomes. They are usually 
balanced. 
Robertsonian translocation, named after WRB Robertson, describes the fusion of 
two acrocentric chromosomes near the centromere region. Usually the short arm 
of the chromosomes is lost in this chromosomal aberration. Often Chromosomes 
13 and 14 are involved (Q Mu, 2010; M Nambiar, 2008). 
There are two main consequences of chromosomal translocations:  
1. A proto-oncogene can come under the influence of a different promoter or 
enhancer, which can lead to an altered expression of the oncogene. 
2. Two genes can fuse so that a new gene is created with a modified function 
(TH Rabbitts, 1994). 
For both mechanisms, it is important that the reading frame is preserved  
(T Burmeister, 2000). 
 
1.2.3.1 Overexpression of an oncogene 
Proto-oncogenes are genes with a crucial role in cell physiology, cell differentiation 
or regulation of cell growth. A proto-oncogene can be activated or deregulated by 
genetic alteration and change into a real oncogene, which may promote malignant 
growth and in this way can contribute to malignant transformation. A common 
mechanism is juxtapositioning the proto-oncogene with a different promoter or 
enhancer (T Burmeister, 2000). Often immunoglobulin (Ig) or T-cell receptor (TCR) 
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gene regions are involved in that kind of chromosomal change. These gene 
regions are the only ones that are rearranged regularly in germ line DNA. This 
process takes place to generate active antigen-receptor genes. However, 
occasionally errors occur and other genes get rearranged instead. 
This mechanism was discovered for the first time in Burkitt’s Lymphoma. To date, 
three translocations have been associated with this B-cell malignancy. With 90 % 
of the cases, translocation t(8;14)(q24;q32) is the most frequent. The result is the 
juxtaposition of cMYC on Chromosome 8 with the immunoglobulin heavy chain 
(IgH) locus on Chromosome 14 (TH Rabbitts, 1994). The translocation occurs in 
the switch region of the IgH constant chain gene segments (JL Hecht, 2000; 
 M Nambiar, 2008). In this way, cMYC is relocated near the enhancer of IgH, 
which leads to an alteration of its expression. cMYC has an important role in cell 
proliferation, differentiation, apoptosis and metabolism (stem cell renewal). In this 
way, overexpression of cMYC would have a great impact on multiple cellular 
processes. This may ultimately contribute to the malignant transformation. Other 
translocations position cMYC close to immunoglobulin light chain (IgL) κ 
(t(2;8)(p11;q24)) or IgL λ (t(8;22)(q24;q11)) (TH Rabbitts, 1994, F Mitelman, 
2007). These processes are presumably also linked to the switch of recombination 
of Ig genes. Thus these chromosomal changes do not explain the entire 
transformation. In addition, mutations in components of the p53 pathway (e.g. p53, 
p19, ATM) have been reported in Burkitt’s Lymphoma patients (M Nambiar, 2008; 
AR Ramiro, 2006). Another example of overexpression of an oncogene is the 
translocation t(14;18) in follicular lymphomas. This translocation relocates the 
BCL2 gene in the direct neighborhood of the enhancer of IgH on Chromosome 14. 
This results in an overexpression of BCL2, which leads to higher cell survival due 
to the (unregulated) anti-apoptotic qualities of BCL2. 
Both examples are illustrated in Figure 1.1 (M Nambiar, 2008). 
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Figure 1.1: The figure illustrates one mechanism of how chromosomal translocation can contribute to 
malignant transformation. It displays the juxtaposition of the coding region of a proto-oncogene (gene A) with  
a promoter or enhancer of a different gene (gene B). This results in an altered expression of the oncogene 
and effects to the cell, depending on the function of the dysregulated gene. Two examples are shown in more 
detail: a) Follicular Lymphoma: The coding region of the BCL2 gene (Chromosome 18) is relocated next to the 
enhancer of IgH (Chromosome 14). This enhances the anti-apoptotic functions of BCL2 in the cell. b) Burkitt’s 
Lymphoma: In the case of Burkitt’s Lymphoma cMYC (Chromosome 8) is positioned next to the IgH enhancer 
by the translocation. 
The lines represent double-stranded DNA, whereas the boxes represent exon regions. The black arrows in 
the first line indicate the breaking points. Adapted from M Nambiar, 2008. 
 
1.2.3.2 Generation of a fusion gene 
The other way in which a translocation can affect leukemogenesis is through 
chromosomal breaks within genes. Usually this happens in an intron region. If the 
reading frame is preserved, a chimeric fusion gene is generated (see Figure 1.2). 
The attributes of the chimeric genes can differ compared to the original function. 
The first cytogenetic abnormality that could be linked to cancer was the 
translocation t(9;22)(q34;q11) in chronic myeloid leukemia (CML) (A de Klein, 
1982; JD Rowley, 1973). This translocation leads to a fusion of the Abelson’s 
tyrosine kinase (ABL) gene on Chromosome 9q34 and the gene “break point 
cluster region” (BCR) on Chromosome 22q11. ABL codes, as the name indicates, 
for a tyrosine kinase, which shows, after its fusion with BCR, an increased activity 
(N Heisterkamp, 1985). 
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Figure 1.2: This figure demonstrates the generation of a fusion protein, also referred to as a chimeric gene, by 
chromosomal translocation. A chromosomal translocation can cause a fusion of the functional domains of e.g. 
gene A with a functional domain of gene B. The result is a new protein with altered or enhanced function. This 
new protein can, depending on the function, contribute to malignant transformation. Two examples are 
displayed above:  
Left side: Chronic Mylogenous Leukemia: CML is characterized by a translocation involving Chromosomes 9 
and 22. The affected genes are ABL on Chromosome 9 and BCR on Chromosome 22. The relevant gene 
fusion is located on Chromosome 22, which is commonly known as Philadelphia Chromosome. The resulting 
protein holds the tyrosine kinase of ABL. But due to the BCR part, the tyrosine kinase has a higher activity.  
Right side: The figure depicts a common translocation in breast cancer. NTRK3 is also a tyrosine kinase and 
is fused to ETV6, which is a transcription factor. The chimeric protein that is encoded by the fusion gene 
contributes to the tumor development. 
The lines represent double-stranded DNA, whereas the boxes represent exon regions. The black arrows in 
the first line indicate the breaking points. Adapted from M Nambiar, 2008. 
 
Also other fusion genes involved in malignant transformation contain tyrosine 
kinases. About 30 out of 90 protein tyrosine kinases can be connected with cancer 
(SD Turner, 2006). Depending on their alteration, timing or level of expression of 
the affected tyrosine kinases, they can directly or indirectly induce transforming 
events such as uncontrolled cell growth, genomic instability or protection of DNA-
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damaged cells from apoptosis. Examples would be NPM-ALK, TEL(ETV6)-JAK2 
or TEL-PDGFβR (SK Bohlander, 2000). 
 
1.3 ETV6 
ETV6 (ets variant gene 6), which was formerly named TEL (translocation ets 
leukemia gene), is a member of a family of transcription factors known as the ets 
(erythroblast transformation specific) family. Most members of the ets family act as 
transcriptional activators. Only three members, namely YAN, ERF and ETV6 show 
functions as repressors of transcription (AD Sharrocks, 2001). 
ETV6 has highly conserved protein domain in common with other family members 
e.g. the ets domain or the HLH (helix loop helix) domain (T Oikawa, 2003;  
CM Slupsky, 1998; B Wasylyk, 1993). ETV6, however, is comprised of 652 amino 
acids and has two alternative variants of two alternative start codons at position 1 
and at position 43 (SJ Grimshaw, 2004). The functional domains are depicted in 
Figure 1.3. 
 
 
Figure 1.3: This figure depicts the functional domains of ETV6. The translocation breakpoints of diverse fusion 
partners are shown as well. Adapted from SK Bohlander, 2005. 
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1.3.1 ETV6 function 
ETV6 is widely expressed throughout the embryonic development in multiple 
organs. Although it was not possible to show a special role in embryonic 
hematopoiesis, there is a certain function of ETV6 in vascular development 
(LC Wang 1997).  
In adults as well, ETV6 shows a wide expression over different organs including 
hematopoietic cells (LC Wang 1998). Hock et al. established mouse models to 
determine the further tasks of ETV6 in hematopoietic cells. They found that 
hematopoiesis is dependent on the expression of ETV6. Further they could show 
that hematopoietic stem cells (HSC) lacking ETV6 have a limited clonal lifespan 
and therefore indicates that ETV6 could have an important role in HSC survival. 
This would indirectly affect most hematopoietic cells, which are dependent on 
continuous regeneration due to their limited lifespan. 
It was also shown that ETV6 has a great impact on the late development of the 
megakaryocyte lineage. ETV6 seems to act along with other transcript factors in 
this process (H Hock, 2004). Recent studies with transgenic mice models implied 
a distinct role of ETV6 is expanding erythroid precursors and the accumulation of 
hemoglobin (M Eguchi-Ishimae, 2009). 
 
1.3.2 ETV6 fusions 
From the use of cytogenetic techniques, it is known that the short arm of 
Chromosome 12 is involved in multiple chromosomal rearrangements in different 
types of leukemia and myelodysplastic syndrome (H Kobayashi, 1994; MD Odero, 
2001). ETV6 is located on Chromosome 12p13 and is involved in more than 40 
chromosomal translocations. Some fusion partners are very well known genes in 
leukemogenesis, such as ABL1 and RUNX1. Others are not known and lack any 
obvious function (SK Bohlander, 2005).  
Translocations in the ETV6 region can be classified in three rough groups. One 
group contributes to leukemogenesis through activation of protein tyrosine kinases 
(PTK). The second group forms fusion genes of ETV6 with transcription factors 
and other genes. The third group does not lead to a productive fusion protein and 
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therefore is presumably involved in the development of leukemia via 
overexpression of itself or neighboring genes. Certainly, this is only a vague 
summarization (see Figure 1.4). There are overlaps, such as translocations that 
show overexpression of a transcription factor. Those translocations would fit into 
group two and three (SK Bohlander, 2005). 
 
1.3.2.1 Protein tyrosine kinases as fusion partners of ETV6  
Fusions of ETV6 with PTKs have been identified in different hematological (and 
non-hematological) malignancies, namely CMML, AML, early pre-B-ALL, T-ALL, 
atypic CML, myelodysplastic syndrome, peripheral T-ALL and some rare solid 
tumors. Fusion partners of ETV6 that gain transformation potential through 
mechanisms such as constitutive activation of the PTK domain, 
autophosphorylation of the fusion protein or phosphorylation of other cellular 
proteins are ABL1, ABL2, JAK1, NTRK3, FGFR3 and SYK (SK Bohlander, 2005). 
The transformation potential of ETV6/PTK fusions is dependent on the presence 
and proper function of the pointed domain of ETV6 and the PTK domain of the 
fusion partner. For example, for the fusion of ETV6 with PDGFRβ (platelet derived 
growth factor receptor β), it was shown that the ETV6/PDGFRβ fusion seems to 
have transformation potency and to be critical for the development of chronic 
myelomonocytic leukemia (CMML) (TR Golub, 1994).  
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Figure 1.4: This figure depicts the translocation partner of ETV6. The colored fields mark the groups of genes 
that share a certain function. A gene fusion is indicated through a connecting line. Arrows point out that the N-
terminal part of the fusion gene is more centrally located. Red arrows indicate transcriptional upregulation. 
Question marks designate that relevance is not yet proven. Adapted from SK Bohlander, 2005. 
 
1.3.2.2 Transcription factors as fusion partner of ETV6 
In different hematopoietic malignancies, fusion genes of ETV6 with transcription 
factor have been described. The most common translocation involves RUNX1 
(AML1) and occurs in approximately 25 % of all childhood B-cell ALL cases  
(SA Shurtleff, 1995). The translocation t(12;21)(p13;q22) shows a more complex 
rearrangement that also includes material from Chromosome 1 (SK Bohlander, 
2005; TR Golub, 1994). The fusion protein of ETV6 and RUNX1 consists of the 
pointed and central domain of ETV6 and the binding specific side of RUNX1. That 
means that the fusion protein can still bind the usual targets of RUNX1. Only, 
instead of transcriptional activation of its target genes, ETV6/RUNX1 shows 
repressive activity. This is mediated through the SAM and the central domain of 
ETV6 (R Fenrick, 1999; SW Hiebert, 1996). 
Another example of a fusion of ETV6 with a transcription factor is the fusion with 
MN1, which is only observed in some patients with AML or Myelodysplastic 
Syndrome (MDS). The MN1/ETV6 fusion protein presumably has transformation 
activity and interacts with transcriptional co-activators, p160 and p300 (A Buijs, 
2000; KH van Wely, 2003). Later it was shown by the same group, that MN1/TEL 
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represses RAR (retinoid acid receptor)-RXR. This action is mediated through the 
dysfunction of a transactivation domain (KH van Wely, 2007). 
The fusion HLXB9/ETV6 has only been described in two cases of childhood AML, 
although the t(7;12)(q36;p13) occurs in about 20 % of childhood AML. The fusion 
protein probably deregulates the expression of ETV6 target genes in early 
hematopoietic cells (HB Beverloo, 2001). 
 
1.3.2.3 ETV6 rearrangements leading to ectopic or aberrant expression 
There are a number of translocations involving ETV6 that play a role in 
leukemogenesis, presumably due to overexpression of one of the fusion genes or 
neighboring genes. Most of these fusions have only been shown in rare cases, 
mostly in acute leukemia. For example, the translocation t(12;13)(p13;q12) was 
detected in some cases of AML. It leads to a fusion of ETV6 with the homeobox 
related gene CDX2 (A Case, 1999), only, no fusion protein was found. Instead, 
CDX2 itself was highly overexpressed. Later it was proven in a murine bone 
marrow model that this overexpression is the important factor for leukemogenesis 
(VPS Rawat, 2004).  
For BLT (Brx-like translocated in leukemia) it was shown that rather the ectopic 
expression of GSH2 than one of the two fusion proteins has a crucial part in the 
development of AML (J Cools, 1999; 2002). 
However, there are also translocations involving ETV6 and previously not 
identified genes. Examples of these genes would be MDS2 and STL. The fusion of 
ETV6 with MDS2 was detected in one case of Myelodysplastic Syndrome, 
whereas STL was identified in one case of pre B-ALL. Both fusions code for very 
small proteins with no detectable function. This suggests that upregulation of 
neighboring genes is the main pathogenic mechanism. Possible affected genes 
could be ID3, E2F2 or RPL11 in the case of the translocation involving ETV6 and 
MDS2 and OSTL in the case of the fusion of ETV6 with STL (SK Bohlander, 
2005). 
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1.4 Translocation t(6;12)(q23;p13) 
t(6;12)(q23;p13) is one of the translocations that involves ETV6 and a previously 
unknown gene. The fusion partner was named STL (six twelve leukemia) gene by 
Suto et al. in 1997. The translocation t(6;12)(q23;p13) was first discovered in a 
precursor B-cell ALL cell line (SUB-B2), which was established from the leukemic 
cells of a 5-year-old boy with common ALL (LQ Zhang, 1993). To date, this 
translocation is unique. But two cases exist with the similar breakpoint 
t(6;12)(q21;p13) discovered in children with pre-B ALL (Y Hayashi, 1990). 
Fluorescence in situ hybridization (FISH) analysis with specific probes for 12p was 
necessary to discover t(6;12)(q23;p13) in the SUB-B2 cell line. Still it is possible 
that these cases are not really different from the cases with t(6;12)(q21;p13) 
discovered by Hayashi et al. 
As ETV6 translocations often show an open reading frame (ORF), it was the first 
hypothesis that a new fusion gene had been discovered with this translocation. But 
an ORF could not be identified either in the ETV6/STL fusion or in the reverse 
fusion. ETV6/STL only codes for a very small protein, which lacks any function 
(see Figure 1.5) (Y Suto, 1997).  
 
 
Figure 1.5: This figure depicts a diagram of the ETV6, ETV6/STL, and STL/ETV6 proteins. Adapted from Suto, 
1997. 
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Because the fusion proteins did not seem to have any impact on the malignant 
transformation or any other detectable function, another previously unknown gene 
came into the focus of interest, because of its direct proximity to the translocation.  
 
1.5 OSTL (opposite STL) 
The newly discovered gene shares the first exon with STL but is transcribed in the 
reverse direction. This led to the name “opposite STL” (OSTL). It is localized at the 
band q23 in the chromosome 6. In human genome OSTL encodes for a protein 
with 275 aa, whereas the mouse protein consists of 307 aa. The mouse OSTL 
protein is 98 % identical to the human OSTL protein and puffer fish (Fugu 
rubripes) OSTL protein and human OSTL protein show a homology of 68 %  
(L Fontanari Krause, 2006).  
The OSTL gene, respectively the encoded protein, were characterized in detail by 
Fontanari Krause et al. The OSTL protein is mainly located in the cytoplasm of 
mouse fibroblast cell lines. The protein does not show very high expression either 
in human or in mouse tissue. OSTL expression could be observed in skeletal, 
muscle, heart, testis, ovary, placenta, prostate and pancreas in human multiple 
Northern blots. In mouse Northern blots, it was only expressed in testis, ovary and 
liver. Northern blots were also performed with human leukemic cell lines, but only 
three EBV transformed lymphoblastoid cell lines (LCL B, D and R) and one 
transformed B-NHL cell line (Karpas422). Reverse trascription PCR experiments 
revealed expression of OSTL in naïve memory B-cells and plasma cells. This 
could indicate a particular role of OSTL in B-cell maturation. Using whole mount in 
situ hybridization experiments on mouse embryos, Fontanari Krause et al. were 
able to detect OSTL in somites (myotome), first and second branchial arches, 
optic and otic vesicles, in the hair follicles of the vibrissae, and limb buds in mouse 
embryos examined from days 9.5 to 14.5. This could indicate that OSTL also has 
a particular role in the embryonic development of these structures. 
Although there were several different splicing variants of OSTL detectable, only 
about seven seem to code for a long protein with functional domains. In fact the 
protein OSTL codes for, carries three functional domains: a N-terminal variant 
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RING (really interesting new gene) finger, a C-terminal RING finger and an In-
between-RING-finger (IBR) domain. These domains show homologies to other 
human genes, C. elegans, D. melanogaster and S. cerevisae. This implies a high 
conservation in evolution.  
The RING motive can be found in more than 400 proteins. They present with many 
different functions. A certain group of proteins can be summarized under the name 
RING-IBR-RING/TRIAD. This protein family is known to have the function as E3 
ubiquitin ligase (AD Capili, 2004). This motive equals the structure of the OSTL 
protein. 
The proteins HAX-1 and SIVA could be identified as interaction partners of OSTL 
by a yeast two-hybrid assay and confirmed by a co-immunoprecipitation assay. 
Both proteins are involved in B-cell survival and B-cell receptor signaling, although 
in opposite ways.  
As the functional structure of OSTL equals the RING-IBR-RING/TRIAD, OSTL was 
tested whether it also shows ubiquitin ligase activity. If this is the case, HAX-1 and 
SIVA are not substrates. Both show no ubitiquination in an ubiquitination assay  
(L Fontanari Krause, 2006). 
 
 
1.6 Aim of this work 
Our main interest in this work was to receive more information about the OSTL in 
the context of leukemia. Especially we were interested in how OSTL is expressed 
in different types of leukemia. This way we hoped to find a correlation between the 
overexpression of OSTL and a certain leukemia subtype. 
Therefore we performed Microarray analysis of 129 leukemia patients for a rough 
overview of the expression levels of OSTL. Then we validated these results using 
real-time PCR. For this study, we included 40 patients with acute leukemia or 
chronic myeloid leukemia.  
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals, kits and materials 
Material Company 
1-kb-DNA molecular weight marker Life Technologies, Eggenstein, 
Germany 
1.5 ml micro centrifuge tube Eppendorf, Hamburg, Germany 
15 ml polypropylene conical tubes Becton Dickinson, Meylan, France 
50 ml polypropylene conical tubes Becton Dickinson, Meylan, France 
Acetic acid  Merck, Darmstadt, Germany 
Agarose ICN Biomedicals Inc. 
Ampicillin Pan Biotech, Aidenbach, Germany 
Aqua bidest.  Millipore, Eschborn, Germany 
Boric acid  Carl Roth, Karlsruhe, Germany 
Bovine serum albumin Life Technologies, Eggenstein, 
Germany 
Cell culture medium DMEM  Pan Biotech, Aidenbach, Germany 
Cell culture medium RPMI  Pan Biotech, Aidenbach, Germany 
Chloroform  Sigma, Deisenhofen, Germany 
Deoxyribonuclease I, Amplification 
Grade 
Life Technologies, Eggenstein, 
Germany 
DEPC  Carl Roth, Karlsruhe, Germany 
DMSO  Sigma, Deisenhofen, Germany 
DNA polymerases Fermentas GmbH, St. Leon-Rot, 
Germany 
dNTP Set, PCR Grade Life Technologies, Eggenstein, 
Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Electroporation cuvettes  PeqLab, Erlangen, Germany 
Eppendorf tubes  Eppendorf, Germany 
Ethanol  Merck, Darmstadt, Germany 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
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Fetal Bovine Serum  Gibco, Life Technologies, Paisley, 
Scotland 
Beveled Filter Tips (different sizes) Starlab GmbH, Ahrensburg, Germany 
Isopropanol Carl Roth, Karlsruhe, Germany 
MicroAmp® Fast Optical 96-Well 
Reaction Plate with Barcode, 0.1 ml 
Applied Biosystems, Foster City, USA 
MicroAmp® Optical Adhesive Film Applied Biosystems, Foster City, USA 
O'Range Ruler, 50bp DNA Ladder Fermentas GmbH, St. Leon-Rot, 
Germany 
PBS Pan Biotech, Aidenbach, Germany 
Penicillin/Streptomycin Pan Biotech, Aidenbach, Germany 
Pipette tips Carl Roth, Karlsruhe, Germany 
Plastic material for cell culture Greiner Labortechnik, Frickenhausen, 
Germany 
Sarstedt, Nümbrecht, Germany 
Corning, USA 
RNase Away Carl Roth, Karlsruhe, Germany 
ThermoPol Reaction Buffer   New England Biolabs GmbH  
Thermoscript RT-PCR System Life Technologies, Eggenstein, 
Germany 
Tris Carl Roth, Karlsruhe, Germany 
Trypan blue Life Technologies, Eggenstein, 
Germany 
Trizol Life Technologies, Eggenstein, 
Germany 
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2.1.2 Equipment 
 
7900HT Fast Real-Time PCR System with Fast 96-Well Block Module (Applied 
Biosystems, USA) 
Centrifuge 5417 R (Eppendorf, Germany) 
Centrifuge 5417 C (Eppendorf, Germany) 
Cytospin (Cytospin 2 Shandon, USA) 
Gel Electrophoresis System (Labortechnik GmbH, Germany) 
GeneAmp PCR System 2400 and 9700 (Applied Biosystems, USA) 
Microscope (Zeiss Axiovert 200 M, Zeiss Axiovert 135, Germany) 
Nano Drop (Thermo Fisher Scientific Inc., USA) 
Pipetman-Pipetts (Gilson Inc., USA) 
UV Spectrophotometer (Pharmacia Biotech, Germany) 
 
2.1.3 Buffer and solutions 
DEPC treated water 
Diethylpyrocarbonate was added to bi-distilled water to reach a 0.1% solution. The 
mix was then stirred with a stir bar over night at room temperature and on the next 
day autoclaved for 30 min. 
 
EDTA (ethylene diamine tetraacetic acid) 
For 500 ml stock solution of 0.5 M EDTA (pH 8.0), 93.05 g EDTA disodium salt 
was dissolved in 400 ml deionized water. To achieve a complete solution of EDTA 
disodium salt, the pH had to be adjusted to 8.0. This was achieved by adding 
NaOH under continuous stirring until the desired pH was reached. Once the pH 
was adjusted, the volume of the solution was adjusted with deionized water to the 
total volume of 500 ml and autoclaved. 
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TBE-Electrophoresis Buffer 
To prepare 1 liter of 10 x TBE buffer, as stock solution, 108 g Tris base, 55 g Boric 
acid and 40 ml 0.5 M EDTA (pH 8.0) were transferred into a 1 l glass flask. Then 
bidest. water had to be added to adjust the solution to a total volume of 1 l. The 
contents were then stirred with a stir bar until all the ingredients had dissolved. 
The buffer was stored at room temperature and discarded if a precipitate formed. 
For agarose gel electrophoresis, a 1:10 dilution was prepared to achieve 1 x TBE 
Buffer. 
 
2.1.4 Cell lines 
DG-75: 
Cell type:  Human Burkitt's Lymphoma cells 
This cell line was established from the pleural effusion of a 10-year-old boy with 
refractory Burkitt's Lymphoma in 1975. 
(Provided by Medhani Mulaw Ph.D., Helmholtz Zentrum, Munich) 
Ben-Bassat et al., Int J Cancer (1977) 
 
LCL B: 
Cell type: Lymphoblastoid transformed cell 
(provided by Dr. Luciana Fontanari Krause, Helmholtz Zentrum, Munich) 
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SEM: 
Cell type: Precursor B cell of type B-I 
The cell line was established from the peripheral blood of a 5-year-old girl at 
relapse of acute lymphoblastic leukemia (ALL) in 1990. The girl was reported to 
carry the t(4;11) MLL-AF4 translocation. 
(provided by Dr. Luciana Fontanari Krause, Helmholtz Zentrum, Grosshadern, 
Munich) 
Greil et al., Br J Haematol (1994) 
Marschalek et al., Br J Haematol (1995) 
 
2.1.5 Media 
DMSO freezing medium 
Cells were frozen in filter-sterilized and heat-inactivated FCS with 10 % DMSO. 
 
Cell culture medium  
To complete the RPMI and DMEM media, 10 % fetal calf serum (heat-inactivated) 
and 1 % Penicillin/Streptomycin solution (10.000 U/ml Penicillin, 10 ng/ml 
Streptomycin) were added to RPMI or DMEM medium to achieve a total volume of 
500 ml. 
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Dulbecco´s Modified Eagle medium (DMEM) 
4.5 g/l Glucose 
0.5 g/l L-Glutamine 
0.1 g/l Sodium Pyruvate 
3.7 g NaHCO3 
Sterile filtered 
 
Penicillin/Streptomycin solution 
10,000 U/ml penicillin 
10 mg/ml streptomycin 
 
Roswell Park Memorial Institute culture medium (RPMI 1640) 
0.02 g/l L-Glutamine 
2.0 g/l NaHCO3 
Sterile filtered 
 
2.1.6 Patients 
The Laboratory for Leukemia Diagnostics, Department of Medicine III, Klinikum 
Grosshadern, provided cDNA samples from anonymous leukemia patients. 
The study includes 10 patients with CML, 10 AML patients with normal karyotype 
(AML,nk) and 20 ALL patients from 4 different subgroups (5 samples of ALL, 
Philadelphia Chromosome positive (ALL-Ph+); 5 patients with the translocation 
t(4;11); 5 patients with common ALL and 5 patients with T-cell ALL). 
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The table displaying the individual patients included in the relative quantification 
experiments can be found in the Appendix. It shows the type of leukemia, age at 
diagnosis, karyotype and molecular marker of each patient.  
Sample 12 (ALL-Ph+) could not be included because of too little cDNA material. 
 
2.1.7 Plasmids 
pGBKT7/OSTL maxi  
pGBKT7/OSTL midi 
pGBT9/E06 mini 
pMIG/OSTL maxi 
The plasmids were prepared and provided by Dr. Luciana Fontanari Krause, 
Helmholtz Zentrum, Munich, Germany. They were used for primer testing and 
optimization before they were used for real-time PCR. In real-time PCR 
experiments the plasmids were used as positive control. 
 
2.1.8 Primers and probes 
Oligonucleotides used for DNA amplification and real-time PCR were designed 
using the MacVector ™7.0 software program as well as Primer Express and were 
purchased from Metabion GmbH (Martinsried, Munich). The sequences of the 
primers and probes are listed in Table 2.1. As endogenous controls, we used 
standardized ready-made primer and probe sets provided by Applied Biosystems, 
USA (see Table 2.2). 
The fluorogenic probes are specifically designed for each primer pair. The 5’-end 
of the oligonucleotide probes are labeled with a fluorescent reporter dye. For this, 
we used FAM dye. On the 3’-end a quencher is bound, which reduces the 
fluorescence emitted by the reporter dye, while the probe is intact. As quencher 
we used BHQ-1. 
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Table 2.1:  This table displays the names of the primers used in this study, the corresponding sequence and 
the Exon, where the primers bind. 
Oligoname Sequence Exon 
hTBP-F 5’-GCACAGGAGCCAAGAGTGAA-3’ Exon 5/6 
hTBP-R 5’-GTCTGAGTGTGGCAGGGACTC-3’ Exon 6 
hGAPDHT 5’-GCACCACCAACTGCTTAGCACC-3’ Exon 7 
hGAPDHB 5’-GTCTGAGTGTGGCAGGGACTC-3’ Exon 9 
E06OSTL601T 5’-AGAGGAATGCCCAGAAGTGTCC-3’ Exon 3 
E06OSTL761B 5’-ACTGAGGTTTGATGTGTGGTCTCC-3’ Exon 4 
E06OSTL196T 5’-TGTGCGAGGAGTGCCTCAAAG-3’ Exon 1d 
E06OSTL381B 5’-TGGTGCTGGAATCAATACGGC-3’ Exon 2 
E06OSTL374T 5’-CAGCACCAAGCCATGTCCTC-3’ Exon 2 
E06OSTL501B 5’-AACACCAGACGAATTGGCAGG-3’ Exon 3 
E06OSTL734B 5’-AAATCGGAGCTGGCGGTATC-3’ Exon 4 
OSTL-436/536FW 5'-CCCTTCCAGATCAGAAAGCAAA-3' Exon 2/3 
OSTL-436/536RV 5'-TGCAGTTAACACCTTCATTCCAA-3' Exon 2/3 
OSTL-436/536Probe 5'-ACAAAATCCAGTGCCCTACCTGCCAATTC-3' Exon 2/3 
OSTL-574/647FW 5'-GGCCAGCGAAATTGAGCAT-3' Exon 3/4 
OSTL-574/647RV 5'-CAGTTCGCTGGATGTGGATCT-3' Exon 3/4 
OSTL-574/647Probe 5'-AGGAATGCCCAGAAGTGTCCAAAGTGC-3' Exon 3/4 
OSTL-783/883FW 5'-TCCCAGAGAGACCTCATTTAAGGA-3' Exon 4/5 
OSTL-783/883RV 5'-CCCTAGTGCCAATCCCAAAA-3' Exon 4/5 
OSTL-783/883Probe 5'-CGAGGGTCAGTCTGTGCTGGAAAATT ATTCAT-3' Exon 4/5 
OSTL-861/961FW 5'-TGGTTTTGGGATTGGCACTAG-3' Exon 5/6 
OSTL-861/961RV 5'-TGTCCGTGATCGTTTTCTCTGT-3' Exon 5/6 
OSTL-861/961Probe 5'-CGGTTGTAATCGGTTTATTTGTATTTCCTAT CTATTGCCT-3' Exon 5/6 
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Table 2.2: This table gives details to the endogenous controls used for real-time PCR. 
 
2.1.9 Software 
• Microsoft Excel 2011 for Mac, version 14.1.0 
• Microsoft Excel 2011 for Mac, version 14.1.0 
• Microsoft Power Point 2011 for Mac, version 14.1.0 
• Microsoft Word 2011 for Mac, version 14.1.0 
  For data analysis, text editing and figure management 
• Primer Express® software v3.0 
  For primer design 
• RQ Manager 1.2 
  For data analysis of the relative quantification experiments 
• SDS software 
  Using TaqMan 7500H, set up and data generating for absolute 
quantification experiments 
 
 
 
 
Endogenous Controls 
Human ACTB (beta actin) Endogenous Control (VIC / TAMRA Probe, Primer 
Limited) 
Human GAPD (GAPDH) Endogenous Control (FAM™ Dye / MGB Probe, Non-
Primer Limited) 
Human TBP (TATA-box binding protein) Endogenous Control (VIC / MGB 
Probe, Primer Limited) 
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2.1.10 Internet search 
• BLAST search (Basic Local Alignment Search Tool) for DNA or protein 
sequence homology search 
  http://blast.ncbi.nlm.nih.gov/Blast.cgi 
• DSMZ German Collection of Microorganisms and Cell Cultures (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH) for Information about 
cell lines 
  http://www.dsmz.de/ 
• PubMed for Scientific Literature 
  http://www.ncbi.nlm.nih.gov/pubmed/ 
• Genome Browser for validating DNA sequences 
  http://genome.ucsc.edu/ 
 
2.2 Methods 
2.2.1 Cell culture 
To ensure sterile conditions required for mammalian cell culture, all procedures 
were carried out in a vertical laminar-flow hood (BDK Luft- und Reinraumtechnik 
GmbH). The cells of the cell lines (see chapter 2.1.4) were grown in commercially 
available cell culture flasks and incubated at 37°C in a humid atmosphere 
containing 5 % CO2. All materials used in the laminar-flow hood were sterilized by 
treating the surface with 70% ethanol or UV light for 15 min. For suspension cells, 
commercially available DMEM and RPMI were used that we supplemented with 
10% FCS and antibiotics (100 U penicillin and 100 ng streptomycin/ml). The cells 
were split according to the cell growth rate and density. For cryopreservation of a 
cell line ∼6x106-1x107 vital cells in a logarithmic growth phase were suspended in 
1.5 ml FCS with 10 % DMSO in 1.8 ml in a 1.8 ml cryotube. Before being stored 
permanently in liquid nitrogen, the tubes were placed in a -80°C freezer for 24 
hours. 
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2.2.2 RNA Isolation with Trizol reagent 
The RNA Isolation from suspension cells was performed using Trizol Reagent 
following the manufacturer's instructions. 
The cells were suspended briefly and then counted. 5-10 x 106 cells were selected 
and centrifuged at 1000 rpm for 5 min to pellet the cells. The medium was 
discarded and 1 ml of Trizol Reagent was added and homogenized through 
repetitive pipetting. After incubating for 5 min at 15 to 30°C, 0.2 ml of chloroform 
was added and the tube shaken vigorously for 15 sec. During centrifuging at 
12,000 x g for 15 min, the sample was separated into three phases: a lower red 
phenol-chloroform phase, a whitish interphase containing DNA and an upper 
colorless, aqueous phase containing RNA. The aqueous phase was transferred to 
a new sterile tube. To precipitate RNA, 0.5 ml isopropyl alcohol was added and 
incubated for 10 min. After another centrifugation at 12,000 x g the RNA was 
visible as a pellet. The supernatant could be removed and the pellet washed by 
adding 1 ml 75 % ethanol and mixed by vortexing. Then the sample was 
centrifuged at 7,500 x g for 5 min, the ethanol discarded and the RNA pellet air-
dried for 5 to 10 min. Afterwards, the RNA was dissolved in RNase free water 
through pipetting and the sample incubated for 10 min at 55 to 60°C. The RNA 
was then stored at -80°C. 
Centrifugation was performed at a temperature of 2 to 8°C and incubation steps at 
15 to 30°C. 
 
To determine the quality and yield, the RNA was measured in a UV 
spectrophotometer (Pharmacia Biotech) at the wavelengths of 260 and 280 nm, 
normally diluted 2 µl in 198 µl sterile bidest. water. Each sample was measured 
twice and only accepted if within the linear range of 4 µl/ml to 40 µl/ml. 
The quality was tested with Agarose Gel Electrophoresis. A diluted aliquot was run 
on 1,5 % Gel stained with ethidium bromide. 
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2.2.3 Deoxyribonuclease I treatment 
All RNA used for reverse transcription PCR (cDNA synthesis) was treated with 
Deoxyribonuclease I to increase the purity of the RNA sample. The DNase used 
was included in a kit by Invitrogen. It was purified from bovine pancreas and had a 
specific activity of ≥ 10,000 U/mg. Four tubes were prepared, two with and two 
without Deoxyribonuclease. In the negative samples, the Deoxyribonuclease was 
replaced by Rnase-free water. In a Rnase-free Eppendorf tube 1 µg RNA 
dissolved in DEPC water was mixed with 1 µl 10 x DNase I Reaction Buffer and 1 
µl DNase I (Amp Grade, 1 U/µl). To the reaction mix, DEPC water was added to 
reach 10 µl total mix. The tubes were then incubated for 15 min at room 
temperature. To inactivate Dnase, I 1 µl of 25 mM EDTA was added and 
afterwards heated to 65°C for 10 min. Immediately after this procedure, reverse 
transcription PCR was performed. 
 
2.2.4 Microarray analysis 
For the microarray analysis bone marrow samples of 139 patients were included. 
129 patients were diagnosed with leukemia and 10 showed no signs of disease 
(normal bone marrow). The cohort included 13 leukemia subgroups, namely CML 
(chronic myeloid leukemia), CALM/AF10 positive leukemia, 7 AML subtypes 
(AML_nk with normal karyotype; AML_MLL with MLL rearrangement; AML_M4 
with CBFB/MYH11 fusion; AML_M3 with PML/RARA fusion; AML_M2 with 
AML1/ETO; AML_FLT3 with FLT3 mutation; AML_comp with complex aberrant 
karyotype), and 4 ALL subtypes (ALL_Ph+ with BCR/ABL fusion, ALL_MLL with 
MLL rearrangements, ALL_BA (pre B-cell ALL), ALL (common ALL)).  
A microarray chip contains a glass slide on which abundant DNA fragments of 
certain regions are attached in so called spots. The cDNA or RNA samples are 
labeled with a specific fluorescent dye. The samples will hybridize to the DNA at 
the spots. After hybridization a laser can detect the fluorescence emitted by the 
probes. The emitted fluorescence is proportional to the amount of RNA/cDNA 
added (M Babu, 2004).  
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For this analysis total mRNA obtained from the 139 bone marrow samples was 
used. The samples were processed and analysed on the Affymetrix HG-U133A 
and HG-U133B chips as described by Schoch et al in 2002. Normalization of the 
data set was performed using VSN (Variance stabilization and calibration for 
microarray data) (W Huber, 2002). The expression levels were depicted in a box 
plot generated in the “box plot function”. The expression signal intensities are 
shown on a logarithmic scale. 
 
2.2.5 Agarose gel electrophoresis 
For analyzing the RNA yield and PCR products, agarose gel electrophoresis was 
performed. Although the expected PCR were quite small, between 100 and 150 
bp, usually 1.5% agarose gels were prepared. Therefore 0.75 g agarose was 
heated with 50 ml 1 x TBE Buffer until boiling to dissolve the agerose entirely. 
After 5 min cooling down, ethidium bromide was added to reach a final 
concentration of 0.5 µg/ml. DNA and RNA were prepared with 1-2 µl DNA Loading 
Buffer (10 x) with a higher density than the buffer, to let the sample sink into the 
pockets and visualize the progress on the gel while running. Depending on the 
size of the expected DNA fragment, an appropriate molecular weight marker was 
used (e.g. 50 bp DNA Ladder by Fermentas). The gel then was run between 60-
100 V. The DNA was visualized under UV light (365 nm). 
 
2.2.6 cDNA synthesis (reverse transcription PCR) 
For the purpose of testing the primers under more comparable conditions to 
patient samples, reverse transcription PCR was performed on several cell lines for 
cDNA synthesis. The Thermoskript reverse transcription PCR System by 
Invitrogen was used. All steps were performed according to the manufacturer’s 
suggestions. Before starting, the bench space and the material used were cleaned 
with “RNase away” to prevent RNase contamination. As primer, we chose 
Random-Hexameter for the cDNA synthesis. Always approximately 1 µg RNA was 
used per reaction tube. We prepared four tubes per RNA sample, D+RT+, D+RT-, 
D-RT+ and D-RT- (D = DNase treatment, RT = cDNA synthesis, + = performed,  
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- = negative control). In this way, the procedure could be evaluated concerning its 
success.  
In the first step, 9 µl of the DNase treated RNA samples were transferred into 0.5 
µl reaction tubes and mixed with 1 µl Random-Hexameter and 2 µl of 10 mM 
dNTP mix per tube. This mixture was then incubated at 65°C for 5 min and 
thereafter placed on ice. This was performed to remove possibly formed 
secondary structures of the RNA to improve the cDNA synthesis. Then in each 
tube 4 µl of 5 x cDNA Synthesis Buffer, 1 µl of 0.1 M DTT, 1 µl RNaseOUT  
(40 U/µl), 1 µl DEPC water and 1 µl Thermoskript RT were added. According to 
the scheme above, in two tubes Thermoskript RT was replaced by DEPC water. 
The tubes were then transferred to the thermal cycler where they were incubated 
at 25°C for 10 min, followed by 50 min at 50°C according to the protocol required 
for Random-Hexameter. The reaction was terminated by heating the mix to 85°C 
for 5 min. To the now synthesized cDNA was added 1 µl RNase per reaction and 
then incubated for 20 min at 37°C. 
The cDNA could then be stored at -20°. 
The success of the synthesis was tested by PCR with GAPDH primers, using the 
protocol as follows: 95°C 2 min, then 30 cycles with 30 sec 95°C, 30 sec 60°C and 
30 sec 72°C, followed once by 72°C for 5 min. Also the DNA quantity was 
measured using Nano Drop (Thermo Fisher Scientific Inc.). For this, a 1:10 dilution 
was prepared and vigorously suspended. From this dilution we measured a two-
microliter drop three times. We obtained the following measurements: 
concentration in ng/µl, wavelength A260 and A280, as well as the ratios 260/280 
and 260/230. Samples with an A260/A280 ratio between 1.8 and 2.2 were 
accepted. 
 
2.2.7 Polymerase chain reaction 
Polymerase chain reaction (PCR) is a commonly used technique for DNA 
amplification and is based on a repetition of cycles consisting of denaturation of 
double-stranded template (cDNA or Plasmid), primer annealing and synthesis of 
new DNA sequence with a heat-stable DNA polymerase (taq polymerase). An 
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initial step with a temperature of about 95°C is required for initial complete 
denaturation of the template, as well as finally a prolonged extension step to 
ensure that all single-stranded DNA fragments are fully extended. 
The Platinum Taq DNA Polymerase (Invitrogen) was used according to the 
manufacturer’s instructions. The PCR buffer contained an approved amount of 
magnesium.  
First, a master mix was prepared using sterile tubes, pipettes, and pipette tips 
(sterilized in the UV Stratalinker) with all reagents on ice as described in the 
following paragraphs. 
 
PCR mix per reaction: 
Platinum Taq DNA Polymerase   0.13 µl 
10 x PCR buffer     2.0 µl 
dNTPs (2 mM)     2.0 µl 
5’ Primer (10 µM)     0.5 µl 
3’ Primer (10 µM)     0.5 µl 
Bidest. water      up to 19 µl 
 
19 µl of the reagent mix was pipetted into thin-wall PCR tubes (0.2 ml), 1 µl of 
template DNA (~100 ng) was added in each tube and the sample was placed 
immediately in the thermocycler GenAmp PCR System 2400 and 9700. (Applied 
Biosystems). 
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The conditions for the PCR were programmed as shown below: 
1.  95°C   2 min     initial denaturation  
followed by 20-30 cycles of step 2 - 4: 
2.  94°C   30 sec    denaturation 
3.  55-60°C  30 sec - 1 min  annealing 
 (primer dependent) 
4.  72°C   1 min     elongation 
 (template dependent) 
5.  72°C   5 min     finish elongation 
6.  4°C   ∞     reaction end 
 
The tubes could then be stored at 4°C. 
The result of the PCR was tested with Agarose Gel Electrophoresis using a 0.5 to 
1.5 % gel depending on the size of the expected DNA fragment. 
 
2.2.8 Real-time PCR (quantitative PCR) 
Real-time PCR also known as quantitative PCR (q-PCR) is a modified system 
based on the traditional polymerase chain reaction that uses fluorogenic probes to 
observe the process of the reaction in real time. This method allows quantifying a 
certain DNA fragment absolutely and relatively. There are basically two systems in 
real-time PCR, SYBR Green, a dye that detects all double-stranded DNA and the 
TaqMan Probe System, where the probes only bind a specific sequence. 
For this work, we decided to use the TaqMan system. The specific primer and 
probe sets were designed using Primer Express Software (Applied Biosystems) 
and endogenous control gene sets that were predesigned and provided by Applied 
Biosystems. All reagents and samples used were kept on ice for the whole 
duration of working with them. Only sterile tubes, pipettes as well as filtered pipette 
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tips were used. For each sample, triplicates were prepared to increase the validity 
of the experiment. 
 
General preparations: 
A master mix was prepared for each primer and probe set used in the run. For the 
endogenous controls, 1 µl primer/probe mix was added to 10 µl Universal PCR 
Master Mix (2 x). For the self-designed primer/probes, the mix was prepared as 
follows: 
 
PCR-Mix per reaction: 
10 µl  TaqMan Universal PCR Master Mix (2 x) 
1.5 µl primer forward (10 µM) 
1.5 µl primer reverse (10 µM) 
0.5 µl fluorogenic probe (10 µM) 
 
11 µl of the endogenous control mix and 13.5 µl of the target gene mix were 
pipetted into the designated wells of the Fast Plate. After this, 0.1 µg to 100 µg 
cDNA diluted in 9 µl (endogenous controls) or in 6.5 µl (target gene probes) was 
also inserted into the designated wells so that the final volume was 20 µl per 
reaction. The plates were sealed with optical adhesive covers and then centrifuged 
briefly. The reaction mix had to be located at the bottom of the well and should not 
contain any bubbles. 
The plate could then be placed in the 7500H TaqMan System. Further 
adjustments were done with the SDS software (Applied Biosystems), which is 
connected to the TaqMan System. 
After choosing the plate size and the selected method, the detector had to be 
selected for each well. 
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Cycling Conditions 
Initial steps: 
2 min at 50°C AmpEraseUNG® activation 
10 min at 95°C AmpliTaq Gold® DNA Polymerase activation 
Cycling steps (40 to 45 repetitions): 
15 sec at 95°C melting double-stranded DNA 
1 min at 60°C annealing and extending  
 
 
2.2.8.1 Absolute quantification 
In the case of Absolute quantification, a series of 10-fold dilutions was prepared 
from the target as well as from the standard. For the standard, plasmids (see 
chapter 2.1.7) in known quantities were used. This task of the sample has to be 
chosen in the SDS software: “unknown”, “no template control” and “standard”. 
Finally, the quantity has to be entered into the system. 
The results were presented in the SDS software and shown in standard curves 
based on the Ct-values or could be exported as raw data for further use. 
 
2.2.8.2 Relative quantification 
To prepare for this method, target genes (the genes of interest) and endogenous 
control genes (constantly expressed housekeeping genes for the use of 
normalization) have to be chosen. This task has to be selected in the SDS 
software. 
The results data can be viewed and adjusted with RQ Manager software (Applied 
Biosystems). The data can be exported in graphic illustration as well as a raw data 
set. 
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3 Results 
3.1 Microarray analysis 
To receive a first picture of the expression profile of the OSTL gene we were able 
to use data of existing microarray analyses. The differential expression data of 
OSTL was extracted and a box plot was generated using this data (see Figure 
3.1). The microarray analysis included 129 patients suffering from 13 different 
leukemia types, and 10 normal bone marrow samples. The cohort was composed 
of patients with chronic myeloid leukemia (CML), seven different acute myeloid 
leukemia (AML) subtypes and four subgroups of acute lymphatic leukemia (ALL).  
OSTL shows the highest expression in CML and the lowest expression in the ALL 
subgroups as well as in patients with the CALM/AF10 translocation. The 
expression of OSTL was approximately twice as high in CML compared to AML. 
The data acquired by microarray only represents a trend of the expression. So we 
decided on a real-time PCR analysis to confirm the results. 
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Figure 3.1: The plot in this figure displays the differential expression of OSTL in a cohort of 129 leukemia 
patients and 10 patients with no signs of disease. The box plot shows the expression levels of OSTL 
(IBRDC1) using mRNA samples of normal bone marrow (nBM), CML (chronic myeloid leukemia), CALM/AF10 
positive leukemia, 7 AML subtypes (AML_nk with normal karyotype; AML_MLL with MLL rearrangement; 
AML_M4 with CBFB/MYH11 fusion; AML_M3 with PML/RARA fusion; AML_M2 with AML1/ETO; AML_FLT3 
with FLT3 mutation; AML_comp with complex aberrant karyotype), ALL_Ph+ with BCR/ABL fusion, ALL_MLL 
with MLL rearrangements, ALL_BA (pre B-cell ALL) and ALL (common ALL). The normalized and variance 
stabilized expression values are shown on a logarithmic scale (approximately log 2). Big bars represent 
median, boxes represent the 25-75% quantile range (inter quantile range: IQR) and whiskers represent the 
1.5-fold IQR. Small cycles represent outliners. An expression value was considered as an outliner, if the value 
was more than 1.5 IQR below or above the first or third quantile, respectively. 
The highest expression was found in the group of CML patients. Whereas by trend the groups with the lowest 
expression were the ALL samples as the CALM/AF10 samples. 
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3.2 Quantitative PCR experiments 
In order to validate the expression levels of OSTL that we obtained in the 
microarray analysis, real-time PCR, also referred to as quantitative (q-) PCR, was 
used.  
Real-time PCR can be performed in one step, where reverse transcription and the 
PCR reaction with fluorescence recording are done in one step. The patient 
samples were provided in cDNA. So we used two-step real-time PCR from the 
beginning.  
To validate the real-time PCR assay we tested the primers and calculated their 
efficiency.  
 
3.2.1 Establishment 
3.2.1.1 SYBR Green system 
The SYBR Green System is a widely used real-time PCR system. The SYBR 
Green I fluorescent dye binds all double-stranded DNA and then emits 
fluorescence. The intensity corresponds with the amount of dsDNA in the reaction. 
Specific design of fluorogenic probes is not necessary with this method. We 
designed the primer pairs following all the approved standards. Namely, we just 
selected primer with a length in a range of 18 to 22 bp. The GC percentage was 
between 40 % and 60 % and the melting temperature was selected to be not lower 
than 52°C and not higher than 58°C. We also avoided primer that would form 
secondary structures. For the SYBR Green system it is recommended to have 
short amplicon sizes. So the primer pairs were designed so that they were in the 
range of between 90 bp and 190 bp in length. All primers spanned an exon-exon 
junction to ensure only cDNA was detected. In the figure below, the location of the 
amplicons is displayed in a schematic presentation of the cDNA sequence of 
OSTL.  
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Figure 3.2: This figure depicts the location of the different amplicons in relation to the exons of OSTL. 
Amplicons are represented in green bars and primers as black arrows and the exons of OSTL are depicted as 
light blue bars in this figure. 
 
We performed traditional PCR to examine the primer pairs. The Primers and 
corresponding amplicons are demonstrated in Figure 3.2. In this way we could 
adjust all parameters to the ideal working conditions for the real-time PCR. Thus 
we could expect an optimal performance of the reaction in real-time PCR. First we 
tested the primers in plasmids. For this purpose, we diluted all available plasmids 
with OSTL inserts. The plasmids were obtained from previous experiments  
(L Fontanari Krause). We used a final concentration of 10 ng/µl, which equals 
approximately 1 x 1010 molecules per microliter and performed PCR in the usual 
program with the appropriate annealing temperature for each primer pair. We 
added 1 µl of plasmid dilution per reaction. This means each reaction contained 10 
x 1010 molecules that all held the target sequence. This high concentration 
provided an overflow of target. Under these conditions, most primers seemed to 
work well and produced the expected products. Only with E06-641T/734B 
additional bands appeared. They might have been caused by splice variants that 
are known for the location of the amplicon. 
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 
E06 196T/381B 
E06 374T/501B 
E06 601T/761B 
E06 641T/734B 
SYBR Green System 
Primer and Amplicons 
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Figure 3.3: This PCR experiment was performed to investigate the primers’ quality. We chose the annealing 
temperatures according to the base composition of the primers and set as displayed as follows: E06-
374T/501B and E06-641T/734B: Ta= 54°C, E06-601T/761B: Ta= 57°C. The PCR product was visualized using 
a 1.5 % agarose gel. The expected size of the PCR product is marked on the side in base pares (bp). All PCR 
products appeared at the expected size. Only with E06-641T/734B extra bands appeared for most plasmids. 
 
In the real-time PCR experiment, the reaction needs to work with much smaller 
concentrations of the target. Because of that, we diluted the plasmid pMIG/OSTL. 
We prepared the dilutions in 10-fold steps, so that we obtained final concentrations 
of 100 pg/µl, 10 pg/µl, 1 pg/µl, 0.1 pg/µl and 0.01 pg/µl.  
Then we performed PCR. We always used 1 µl of each plasmid dilution per 20 µl 
PCR reaction mix. The annealing temperatures were set as above. We found that 
the fewer templates we added, the more unspecific products appeared at the size 
of 50 bp. A possible explanation would be primer dimers. As an example, the 
primer E06-641T/734B is shown in Figure 3.3. 
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Figure 3.4: The PCR products of the PCR reaction with the primer E06-641T/734B are shown on a 1.5 % 
agarose gel. The annealing temperature for the reaction was 57°C. On the x-axis the amount of template DNA 
per reaction is stated. The template amount decreases in 10-fold steps from the left side to the right. PCR 
product appeared at the expected size of about 100 bp. In the reactions with 1 pg template and lower, an 
additional band is visible with a size of 50 bp, which could be primer dimers. 
 
The appearance of potential primer dimers could have different reasons. One 
cause would be an inappropriate annealing temperature. This led us to our next 
step, where we tested diverse annealing temperatures. The result, however, was 
not convincing. Even more primer dimers were detectable as shown in Figure 3.5 
for example. 
 
 
Figure 3.5: This figure depicts the PCR product of two dilution series. In both settings, the primer E06-
641T/734B was used. Only the annealing temperature was adjusted to 59°C on the left side and to 52°C on 
the right side of the figure. Very strong primer dimers became visible in both settings. 
 
The next attempt at eliminating the potential primer dimers was by adding  
Q-Solution to the reaction mix. Q-Solution is a PCR reaction additive, which 
E06 641T/734B 
200 bp 
100 bp 
Series of dilutions with the primer pair E06 641T/734B TA:: 57°C 
100 pg         10 pg        1 pg           0.1 pg 
50 bp 
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enhances amplification of templates that are GC-rich or that have extensive 
secondary structure. This solution modifies the melting behavior of nucleic acids. 
This also led to no improvement as is shown in the example Figure 3.6. 
 
 
Figure 3.6:  The figure depicts a 1.5 % agarose gel. The PCR product shown is received from the primer pair 
E06-196T/381B. The bands are expected at 180 bp. The annealing temperature used was 57°C. On the x-
axis the amount of template DNA per reaction is indicated. Q-Solution was added to the reaction mix in order 
to enhance the amplification of the target sequence and to avoid unwanted amplification. But nevertheless 
additional products are visible at the size of about 50 bp especially in reactions with low template amounts 
(arrow). 
 
Another reason for primer dimers could be an abundance of primers. In this way, 
unnecessary needless primers can form primer dimers. We prepared dilutions of 
the primers, although we used a primer concentration within the recommended 
range, namely 0.25 µM. We compared the concentration we normally used, 250 
pM, with the final primer concentrations of the reaction mix of 125 pM, 50 pM and 
25 pM.  The PCR was performed in the usual program (Ta = 57°C) and 10 µg and 
1 µg plasmid as template. As shown in Figure 3.7, the primer dimers disappeared 
in the higher dilution of primers. 
 
E06-196T/381B + Q-Solution 
     100 pg      10 pg         1 pg         0.1 pg       0.01 pg   
200 bp 
100 bp 
50 bp 
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1 = pMIG/OSTL 10 pg, 2 = pMIG/OSTL 1 pg, 3 = dH2O neg. control 
Figure 3.7: Depicted in this figure is a 1.5 % agarose gel. The PCR products are visualized at the expected 
size between 150 bp and 200 bp. The PCR was performed with the primer pair E06-196T/381B in different 
dilutions and an annealing temperature of 57°C. The templates were plasmid pMIG/OSTL, 10 pg and 1 pg per 
reaction. In higher primer concentrations, again non-specific products appear at about 50 bp. But it is shown 
that the non-specific products disappear with lowering primer concentrations. At the concentration of 50 pM no 
products are detectable at 50 bp. 
 
These difficulties in the establishment of the SYBR Green method bear too much 
insecurity to be a reliable experiment and this caused us to reject this method. We 
decided to use the TaqMan System. 
 
3.2.1.2 TaqMan system 
The TaqMan system is also often used for performing quantitative real-time PCR. 
It utilizes specific fluorogenic probes. Therefore it was necessary to design primers 
and corresponding fluorescent probes for the TaqMan System. For this we used 
Primer Express Software. The primer design for this technique follows the same 
rules as displayed for the SYBR Green System. In Primer Express Software, these 
and additional parameters for probe design are represented in a penalty score. 
Lower numbers indicate a primer/probe set that satisfies a greater percentage of 
the parameters contained in a list of requirements for the best possible result. This 
list includes the usual parameters required for primer design, such as GC content, 
melting temperature difference and primer and amplicon length. Probe specific 
conditions are also included, such as primer-probe distance. We only chose 
primer/probe sets with the lowest penalty score for each amplicon size. That 
means the primer constructed for an amplicon size of 101 bp had a penalty of  
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8 or 9. This applies to primer/probe sets OSTL-436/536, OSTL-783/883 and 
OSTL-861/961. The sets for the amplicon size of 51 bp, OSTL-574/647 had a 
penalty of 121, which is due to the very short amplicon length. 
For the probe as well there are requirements that need to be considered in the 
design of the probe. It should also not exceed the GC percentage between 40 and 
60 %. It should avoid runs of an identical nucleotide, especially of guanine. The 
probe should be located on the DNA strand, which lets the probe have more 
cytosine than guanine. The primer should be located as close to the probe as 
possible without overlapping. The probes are labeled with FAM reporter dye 
placed on the 5’-end. The non-fluorescent quencher BHQ-1 is placed on the  
3’-end. 
In Figure 3.8 the position of the expected amplicons and the corresponding 
primers is displayed in relation the exons of OSTL. 
 
 
Figure 3.8: This figure depicts the primers’ amplicons in relation to the exons of OSTL. The exons of OSTL are 
depicted in light blue. The amplicons are colored dark blue and the primers’ names are written on the left side 
of the corresponding amplicon. Black arrows depict the primer.  
 
The primers' performance was first analyzed in traditional PCR. Although 
appearing non-specific, structures such as primer dimer should not be a matter of 
concern using the TaqMan technique. We did not analyze OSTL-574/647, 
TaqMan Primer and Amplicons 
OSTL-574/647 
OSTL-436/536 
OSTL-783/883 
OSTL-861/961 
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 
OSTL 
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because the expected amplicon would have a size of 51 bp. This would be very 
difficult to differentiate between the actual product and primer dimers, which both 
would appear at about 50 bp. We performed a PCR with the primer pairs OSTL-
861/961, OSTL-783/883 and OSTL-436/536 using 100 pg pMIG/OSTL and 
pGBKT7 plasmids as templates (see Figure 3.9). The settings were standard and 
the annealing temperature was adjusted to 55°C. The results were satisfying, 
apart from OSTL-861/961in the reaction with plasmid pGBKT7. In this reaction, the 
band appeared at about 200 bp instead of the expected 100 bp. This primer pair 
spans the junction between exon 5 and 6. Concluding from that, the finding might 
be explained by a splice variant existing in this area (L Fontanari Krause, 2006). In 
this case, pMIG contains one variant and pGBKT7 another one. 
 
 
Figure 3.9: This figure depicts a 1.5 % agarose gel. Displayed are the PCR products using the primer pairs for 
TaqMan PCR: OSTL-861/961, OSTL-783/883 and OSTL-436/536. As template we used order pMIG/OSTL, 
then pGBKT7 plasmids (both times 100 pg per reaction) and bidest. water as negative control. All primers 
were designed to produce an amplicon at the size of 101 bp. As visible in the figure all PCR products have the 
expected size. Only the primer pair OSTL-861/961 shows a band at a size of around 200 bp in the reaction 
with pGBKT7 as template. 
 
Figure 3.10 displays the performance of the primers under lower template 
concentrations. For this, we prepared different dilutions of plasmid pMIG/OSTL in 
10-fold steps starting with 10 pg/µl down to 0.01 pg/µl. With all primer pairs, 
amplification of the amplicons is detectable in all concentrations. Only with OSTL-
861/961 there was no amplification measurable in the reaction using 0.01 pg of 
All taqman primer 
OSTL-861/961 OSTL-783/883 OSTL-436/536 
100 bp 100 bp 
200 bp 
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template. Non-specific products are only detectable in the reaction with the lowest 
concentration of template or in the negative control. 
 
Figure 3.10: In this figure, the products of PCR reactions with the TaqMan primer pairs are displayed on a 
1.5% agarose gel. Different amounts of template were added, from 10 pg plasmid in the left lane over 1 pg 
and 0.1 pg to 0.01 pg plasmid DNA per PCR reaction. For each primer pair, in the fifth lane no template is 
added as negative control. 
 
In the last experiment before we proceeded to the actual real-time PCR 
experiments, we performed a PCR experiment with cDNA of different cell lines as 
template. We compared the performance of the primer pairs in cDNA, which will 
be the actual template in the real-time PCR experiments, and in plasmids. The 
cDNA was transcribed from RNA, which was extracted from the SEM, LCL B and 
DG75 cell lines. SEM is a Precursor B cell of type B-I. LCL B derives from 
lymphoblastoid cells. DG75 is a cell line of human Burkitt's Lymphoma cells.  
The PCR was performed with the primer pairs OSTL-783/883, OSTL-861/961. In 
the DG75 cell line we also used GAPDH primer as positive control (see Figure 
3.12). In SEM the signal visualized in the agarose gel almost equals the signal 
detected from the plasmids' products. With the primer pair OSTL-861/961 two 
bands appeared on the agarose gel, one stronger band at the expected size of 
about 100 bp and a weaker band at about 200 bp. The 200 bp band is detectable 
at the same size as with the plasmid pGBKT7, whereas the 100 bp band is in the 
range of pMIG/OSTL (see Figure 3.11). This is again most likely due to the known 
splice variant of OSTL in the location of the amplicon. 
 
436 & 784 & 861dilutions 
OSTL-861/961 OSTL-783/883 OSTL-436/536 
100 bp 
200 bp 
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Figure 3.11: The figures depict the PCR products of the primer pairs OSTL-783/883 and OSTL-861/961. 
Annealing temperature was set to 55°C and 35 cycles were performed. cDNA from the SEM and LCL B cell 
lines, as well as plasmid pMIG/OSTL and pGBKT7 were used as template. All products appear at the 
presumed size marked by a 50 bp ladder, except OSTL-861/961 in plasmid, pGBKT7, that was visualized at 
about 200 bp. In both cell lines with OSTL-861/961 an additional weaker band is detectable at 200 bp to the 
expected 100 bp product. 
 
In the experiment with the DG75 cell line, no products of OSTL were amplified. 
 
 
Figure 3.12: This figure displays the PCR results of OSTL-861/961and GAPDH primers. As template we used 
cDNA from the DG75 cell line. For the reaction with GAPDH primers, we used an annealing temperature of 
60°C and 30 cycles. For OSTL-861/961 Ta was set to 55°C and 35 cycles were performed. Despite the higher 
cycle number, we were not able to amplify any product with OSTL-861/961 primers from the cDNA of DG75. 
 
3.2.2 Real-time PCR experiments (TaqMan system) 
3.2.2.1 TaqMan primer efficiency  
After pre-examining the primer pairs in detail, we analyzed the primers' and the 
probes' efficiency in the TaqMan system. In order to do so, we performed standard 
curve analysis with all primer/probe sets. For this, the threshold cycles (Ct-values) 
SEM 
OSTL-783/883 OSTL-861/961 
100 bp 
200 bp 
LCL B 
OSTL-783/883 OSTL-861/961 
100 bp 
200 bp 
DG75 
DG75 
GAPDH 
+ 
100 bp 
200 bp 
+ 
OSTL-861/961 
500 bp 
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were determined for a set of dilutions. The threshold cycles were then plotted 
against the logarithm of the template concentrations. If the dilution series are 
prepared in 10-fold steps, the slope should ideally be -3.32.  
The efficiency itself can be calculated from the slope with the Equation 3.1. 
 
 
Equation 3.1: This equation was used for calculating the efficiency of the primer/probe sets. Ex represents 
efficiency. The slope is achieved by standard curve experiments. 
 
We prepared dilution series in 10-fold steps of the plasmid pMIG/OSTL and of 
cDNA. The cDNA was transcribed from RNA of the SEM cell line. 
The results we generated varied a lot over the different primer/probe sets. In the 
following paragraphs, the performance of each primer pair is described. 
 
OSTL-436/536: 
We performed real-time PCR and used dilutions from 100 ng/µl, 10 ng/µl, 1 ng/µl 
to 0.1 ng/µl. This means in the reaction where we added 100 ng, we had about 1x 
1011 molecules in the reaction that hold the target sequence. But even with these 
high amounts, several adjustments and in several repeats, almost no amplification 
was detectable, neither in the plasmid nor in the cDNA cell line. With these poor 
results, we were not able to generate a reliable plot. 
 
OSTL-574/647: 
Here again we used 100 ng/µl, 10 ng/µl, 1 ng/µl and 0.1 ng/µl dilutions for the real-
time PCR experiment. For this very high amount of molecules, low Ct-values could 
be expected. We used plasmids as template at first. However, using the 
primer/probe set OSTL-574/647 we only received Ct-values between 32 and 35 
and found a high variance over the replicates of the same dilution. When we 
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plotted the Ct-values against the log quantity, we obtained a slope of -0.6216  
(see Figure 3.13). From this slope we calculated the efficiency using the Equation 
3.1. The estimated efficiency was 39.62%. 
 
 
Figure 3.13: In this chart we plotted the threshold cycles generated with primer/probe set OSTL-574/647 
against the logarithm of the template concentration. The template was plasmid pMIG/OSTL in the 
concentrations 100 ng/µl, 10 ng/µl, 1 ng/µl and 0.1 ng/µl. The slope generated from the plot was -0.6261 and 
marked in bold. The high variance within the triplicates is apparent. The most extreme example is marked with 
an arrow. 
 
OSTL-783/883: 
We performed standard curve analysis as well with the primer/probe set OSTL-
783/883. For the first experiment with pMIG/OSTL, we used the following 
concentrations: 100 ng/µl, 10 ng/µl, 1 ng/µl and 0.1 ng/µl. Using these high 
amounts of molecules, we received Ct-values of 4 up to 15. To make the plasmid 
experiment more comparable with the one with the cDNA, we diluted the plasmid 
to 10 pg, 1 pg, 0.1 pg and 0.01 pg per reaction and the cell line cDNA 100 ng,  
10 ng and 1 ng per reaction. Then we plotted the Ct-values against the logarithm 
of the concentrations. From these plots we generated the slope (see Figure 3.14). 
For the plasmid dilution we received a slope of -3.3536 and for the cDNA dilutions 
-3.922. With these slopes we calculated the efficiency using the Equation 3.1. We 
obtained an efficiency of 99% for the plasmid dilutions and 80% for the cell line 
dilution. 
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Figure 3.14: These figures display linear functions. They were achieved by plotting the Ct-values of a set of 
dilutions against the logarithm of the added quantity of target. The slope of the function is marked in bold. In 
Figure 3.14 A the template was pMIG/OSTL in the concentrations: 10 pg/µl, 1 pg/µl, 0.1 pg/µl and 0.01/µl. For 
Figure 3.14 B we utilized cDNA from SEM cell line in the following concentrations: 100 ng/µl, 10 ng/µl and  
1 ng/µl. It is apparent that the triplicates of one dilution varied far less in their Ct-values than for example with 
primer/probe set OSTL-574/647. 
 
OSTL-861/961: 
With this primer/probe set, we proceeded in the same way as with OSTL-783/883. 
We first used high concentrations of the plasmid pMIG/OSTL (100 ng/µl, 10 ng/µl, 
1 ng/µl and 0.1 ng/µl) and also received Ct-values between 5 and 18. For better 
comparability, we used lower dilutions of the plasmid and higher concentrations of 
the cDNA. But with 1 ng/µl, we could not detect any amplification. We found a 
slope of -3.4571 for the plasmid dilutions and a slope of -4.5731 for the cell line 
dilutions (see Figure 3.15). With this information, we calculated the efficiency using 
the Equation 3.1. The result for the plasmid dilutions was 95%, for the cell line 
65%.  
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Figure 3.15:  This plot is generated by plotting the Ct-values of a standard curve experiment against the 
logarithm of the quantity added. In Figure 3.15 A, plasmid pMIG/OSTL was used as template in the 
concentrations: 10 pg/µl, 1 pg/µl, 0.1 pg/µl and 0.01/µl and in Figure 3.15 B, the template was cDNA of the 
SEM cell line in the concentrations: 100 ng/µl, 10 ng/µl and 1 ng/µl. No amplification was detectable for the 
reactions with 1 ng template.  
 
To decide which primer/probe set we should use for the relative quantification 
experiments, we took all the results from the traditional PCR experiments into 
consideration as well as the efficiency calculations. The sets OSTL-436/536 and 
OSTL-574/647 were excluded because of the poor performance in the standard 
curve analysis. We rejected OSTL-861/961 because of the splice variant in the 
area where the probe anneals. Also the efficiency was not as good as with OSTL-
783/883. Thus we decided to use the primer/probe set OSTL-783/883 for the 
relative quantification experiments. 
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3.2.2.2 Normalization 
To obtain objective and valid results, the generated data are normalized with 
control genes. These internal control genes function as an active reference and 
can normalize differences in the amount of cDNA.  
We chose the control genes β-Actin, GUSB (Glucuronidase, beta) and TBP 
(TATA-binding protein). TBP showed a very low and unreliable expression pattern 
or was not expressed at all. Therefore it was excluded from the experiment.  
Figure 3.16 depicts the Ct-values generated with the primer/probe sets for OSTL, 
β-Actin and GUSB. We compared the average threshold cycles of the control 
genes with the values of OSTL and decided to use β-Actin for normalization of the 
following experiments. 
 
 
Figure 3.16: This figure depicts the raw Ct-values generated using the OSTL-783/883, β-Actin and GUSB 
primer/probe sets. Each column represents the average Ct-value of a group of patients with a certain 
leukemia. The groups comprise, from left to right, CML, AML (normal karyotype), T-ALL, common ALL,  
ALL-t (4;11) and ALL-Ph+. 
 
3.2.2.3 Patients 
The study includes 10 patients with CML, 10 AML patients with normal karyotype 
(AML-nk) and 20 ALL patients that can be divided into 4 subgroups (5 samples of 
ALL, Philadelphia Chromosome positive (ALL-Ph+); 5 patients with the 
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translocation t(4;11); 5 patients with common ALL and 5 patients with T-ALL). One 
of the ALL-Ph+ samples had to be excluded due to too-little an amount of cDNA. 
Therefore the ALL-Ph+ group only contains 4 samples. 
The Table displaying the individual patients included in the relative quantification 
experiments can be found in the Appendix.  
 
3.2.2.4 Relative quantification 
ΔCt-values 
For relative quantification of the expression levels of the OSTL gene, we 
performed real-time PCR. We acquired the data of these experiments as outlined 
in the Methods section. The Ct-values of OSTL of every patient were normalized 
with the β-Actin Ct-values of the corresponding samples. This resulted in a  
ΔCt-value. Smaller ΔCt-values indicate higher expression and higher ΔCt-values 
therefore lower expression. 
 
Figure 3.17 shows the ΔCt-values of OSTL of every individual patient sample. 
CML patients appear with the smallest ΔCt-values, which means the highest 
expression. Whereas the ALL samples show overall lower expression indicated 
through generally higher ΔCt-values. The ALL subgroups appear with 
heterogeneous expression levels. 
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Figure 3.17: This figure displays the individual ΔCt-values of OSTL in every patient sample. The ΔCt-values 
are normalized with the control gene β-Actin. The patient samples are grouped in the underlying diseases. 
Depicted are the expression levels of 10 CML patients, 10 AML patients and 19 ALL patients. The ALL 
patients are divided into subgroups as follows: 4 patients with ALL, Philadelphia Chromosome positive; 5 
patients with the translocation t(4;11); 5 patients with common ALL and 5 patients with T-cell ALL. 
 
Figure 3.18 demonstrates the average ΔCt-values of every leukemia subgroup and 
the corresponding standard deviation. The myeloid leukemia, CML and AML 
appear with the lowest ΔCt-values (CML 4.36; AML 4.55) meaning the higher 
expression. Only in AML the standard deviation is wider, indicating the highest 
variance over the individual samples. The highest ΔCt-values appear in ALL 
subgroups (in descending order: ALL-Ph+: 8.09; ALL-t(4;11): 7.62; common ALL: 
7.27). An exception in the ALL subgroups is the T-ALL subgroup. The expression 
of OSTL in the T-ALL patients is, with 5.14, more similar to CML and AML than to 
the other ALL samples. 
 
0,00 
2,00 
4,00 
6,00 
8,00 
10,00 
12,00 
CML AML-nk ALL-Ph+ ALL-t(4;11) common ALL T-ALL 
de
lta
 C
t 
Patient 1 
Patient 2 
Patient 3 
Patient 4 
Patient 5  
Patient 6 
Patient 7  
Patient 8 
Patient 9 
Patient 10 
 63 
 
Figure 3.18: This figure depicts the average ΔCt-values of OSTL in CML, AML and all ALL (T-ALL, common 
ALL, ALL-t(4;11), ALL-Ph+). Grey columns represent the ΔCt-values. The ΔCt-value is an indicator for the 
expression. Black bars indicate the standard deviation. All values were normalized with the control gene  
β-Actin. 
 
In Figure 3.19 all ALL subgroups are summarized in one group. Still the 
expression of OSTL in the average of all ALL subgroups is lower than AML and 
CML implicated by the higher ΔCt-value (7.03). CML and AML express OSTL 
almost equally. Only the standard deviation is higher for the AML (1.96) samples 
compared to CML (0.97). The standard deviation of AML almost equals the 
standard deviation of the ALL group (1.92). 
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Figure 3.19: This figure depicts the average ΔCt-values of OSTL in CML, AML and all ALL subgroups 
summarized in one group. The grey columns represent the ΔCt-values. The ΔCt-value is an indicator for the 
expression. Black bars indicate the standard deviation. All values were normalized with the control gene  
β-Actin. 
 
ΔΔCt-values 
The following part displays the comparison of OSTL expression in the different 
types of leukemia. Basically, this method contrasts the expression levels 
(described in ΔCt-values) with a reference (also described in ΔCt-values). This 
results in the difference between ΔCt-values, which are represented as  
ΔΔCt-value. Positive ΔΔCt-values represent lower expression than the reference. 
In this way, negative ΔΔCt-values indicate higher expression than the reference. 
Higher ΔΔCt-values represent a greater difference between the sample and the 
reference. 
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Figure 3.20: This figure depicts the relative quantification of AML (normal karyotype) and ALL. The reference 
is CML. The columns indicate ΔΔCt-values. They are the difference between the sample and the reference. 
 
Figure 3.20 represents a relative quantification. CML is set as reference and 
compared to AML and ALL. The OSTL expression in AML almost equals its 
expression in CML, which is shown by the very low ΔΔCt-value (0.19). The  
ΔΔCt-value of ALL in this figure is higher, with 2.67, indicating a lower expression.  
 
Fold change = 2ΔΔCt 
Equation 3.2: With this equation the fold change between two expression levels can be calculated. ΔΔCt 
describes the difference between the two ΔCt-values of the two compared values. The equation is based on 
the theory that every PCR amplicon doubles in every PCR cycle. 
 
Equation 3.2 is used to calculate fold differences between sample and reference. It 
assumes an efficiency of 100%. However, in the standard curve experiment for the 
primer/probe set OSTL-783/883, the efficiency was only 80%. Taking this into 
consideration, the Equation 3.2 has to be adjusted as shown below: 
 
Fold change = 1.8ΔΔCt 
Equation 3.3: The equation is based on Equation 3.2. It takes the actual efficiency of 80% for primer/probe set 
OSTL783/883 into consideration. 
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Taking this into consideration, OSTL is expressed 4.8-fold higher in CML than in 
ALL. 
Because the ALL subgroups varied in the expression as shown in Figure 3.21, all 
ALL subgroups are depicted separately. The ΔΔCt-values compared to CML differ 
between the ALL subgroups from 0.78 in T-ALL to 3.73 in ALL-Ph+. This means 
that there is only a 1.58-fold difference between T-ALL and CML but almost a  
9-fold difference between ALL-Ph+ and CML. 
 
 
Figure 3.21: This figure depicts the relative quantification of OSTL expression in AML-nk, T-ALL, common 
ALL, ALL-t(4;11) and ALL-Ph+. The reference is CML. The columns indicate average ΔΔCt-values of all 
groups. They represent the difference between the sample and the reference. 
 
Figure 3.22 represents the relative quantification of CML, AML, common ALL, ALL 
t(4;11) and ALL-Ph+ with the reference T-ALL. AML and CML express OSTL at a 
higher level than T-ALL shown by the negative ΔΔCt-values. But the expression 
level is only 1.41-fold higher in AML and 1.58-fold in CML. In all other ALL 
subgroups, OSTL is expressed as lower than T-ALL. The expression level is  
3.5- fold higher in common ALL, 4.3-fold in the ALL with the translocation t(4;11) 
and 5.66-fold in ALL. 
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Figure 3.22: This figure depicts the relative quantification of the OSTL expression in CML, AML-nk, common 
ALL, ALL-t(4;11) and ALL-Ph+. The reference is T-ALL. The columns represent ΔΔCt-values. They represent 
the difference between the sample and the reference. Negative ΔΔCt-values indicate higher expression than 
the reference. Positive bars represent lower expression than the reference. 
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4 Discussion 
OSTL was discovered adjacent to the 6q23 breakpoint of the translocation 
t(6;12)(q23;p13), which leads to the ETV6/STL fusion gene. This translocation 
involves ETV6, which is known to be associated with leukemia development. 
Usually ETV6 fusion genes lead to the generation of a fusion protein with altered 
function. However, this is not the case with the ETV6/STL fusion. The ETV6/STL 
fusion as well as the reciprocal fusion STL/ETV6 only code for small proteins with 
unknown function (Y Suto, 1997). This led the focus of interest to the OSTL gene 
that is next to STL on the long arm of chromosome 6. OSTL shares the first exon 
with STL. But OSTL is transcribed in the opposite direction to STL.  
Figure 4.1 demonstrates the relationship of the genes ETV6, STL and OSTL on 
Chromosomes 6 and 12 under normal conditions and with the translocation 
t(6;12)(q23;p13). 
 
 
Figure 4.1: This figure depicts Chromosomes 6 and 12. ETV6 is located on the short arm of Chromosome 12, 
whereas STL and OSTL are localized on the long arm of Chromosome 6.  STL and OSTL are transcribed in 
opposite directions but share the first exon. On the right, the translocation t(6;12)(q23;p13) is shown. It results 
in an ETV6/STL and an STL/ETV6 fusion. OSTL is not directly affected by the translocation. Adapted from  
L Fontanari Krause, 2006. 
 
Fontanari Krause et al. have examined the OSTL gene in detail. They discovered 
interesting characteristics of OSTL, which allow the hypothesis that OSTL plays a 
role in leukemogenesis. OSTL contains a RING-IBR-RING/TRIAD motive that 
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functions as E3 ubiquitin ligase in other proteins (AD Capili, 2004). But Fontanari 
Krause et al. could not show an ubiquitin ligase function of OSTL. The human and 
the mouse OSTL are highly conserved which suggests that OSTL has an 
evolutionary important function in the cell. The OSTL protein is localized mainly in 
the cytoplasm and it is not restricted to a single tissue. STL shows the same 
expression pattern as OSTL, which suggests co-expression. OSTL is also 
detectable during all stages of B-cell development. This could be an indicator that 
OSTL also plays a role here. It could also be detected during certain periods of 
mouse embryogenesis, which suggests that OSTL is also involved in 
embryogenesis.  
Fontanari Krause et al. identified the proteins HAX-1 and SIVA as interaction 
partners of OSTL. Both proteins are involved in apoptosis, suggesting that OSTL 
also has a role in apoptosis. 
We studied the expression levels of OSTL in different types of leukemia to identify 
a correlation of OSTL with a leukemia subtype. We anticipated an increased 
expression of OSTL in ALL patients. This assumption is based on the fact that the 
translocation was detected first in a young patient with pre-B-cell ALL (Y Suto, 
1997). In addition OSTL was mainly expressed in cells of the lymphatic system  
(L Fontanari Krause, 2006).  
 
4.1 Assessment of the results 
We first used microarray data from 129 patients with different types of leukemia 
(CML and 12 different Acute Leukemia) and normal bone marrow to obtain an 
overview of OSTL expression levels. These analyses showed that OSTL was 
expressed twice as high in CML patients compared to samples from normal bone 
marrow, AML or ALL samples.  
To validate these results we conducted real-time PCR experiments on 39 
leukemia patient cDNA samples, CML showed the highest expression of OSTL, 
which supports the findings of the microarray analysis. However, the expression 
level of OSTL in the CML group was almost identical to the AML group (see Figure 
3.20). Both groups include 10 patients. This offers a good comparability. Though 
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these groups are relatively small, the AML group is genetically more 
heterogeneous than the CML group.  
It is of interest that, in earlier experiments, OSTL seemed to play a bigger role in 
the lymphatic lineage than in the myeloid (L Fontanari Krause, 2006). This makes 
it even more surprising that we found the highest expression of OSTL in myeloid 
leukemia. Our real-time PCR experiments confirmed the results of the microarray 
analysis that OSTL is expressed at lower levels in ALL than in myeloid leukemia, 
especially CML.  
To be precise, OSTL is expressed 4.8-fold lower in ALL patients than in CML 
patients. The ALL group contains 19 patients and is divided into 4 subgroups: 
common ALL, ALL with a t(4;11), T-ALL and ALL-Ph+. The ALL group also shows 
very heterogeneous OSTL expression levels. We expected the highest OSTL 
expression in the ALL-Ph+ since ALL-Ph+ patients, like CML patients, have a 
t(9;22)(q34;q11) translocation leading to the BCR/ABL fusion gene (A deKlein, 
1982; JD Rowley, 1973).  
Very much to our surprise, ALL-Ph+ patients express OSTL at a 9-fold lower level 
than CML patients. In contrast to this, T-ALL patients show very high OSTL 
expression levels, which are almost equal to the expression levels observed in 
myeloid leukemia. The fold change between T-ALL and myeloid leukemia is only 
1.5. Common ALL and ALL-t(4;11) patients have intermediate expression levels. 
They express OSTL 5.5-fold and 6.7-fold lower than CML patients, respectively 
(see Figure 3.21). 
However, both the microarray analyses and the real-time PCR measurements 
detected the highest expression of OSTL in CML patients. Only the fold 
differences varied between the two methods. 
 
4.2 Discussion of the results 
Genetic alterations are the basis of leukemogenesis (T Burmeister, 2000; U Krug, 
2005; H Lodish, 2007; F Mitelman, 2007; JD Rowley, 1999). Translocations play 
an important role, resulting in either the formation of fusion genes (e.g. BCR/ABL) 
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or the deregulation of gene expression (e.g. overexpression of MYC as the 
consequence of the t(8;14) translocation). Fusion genes result in altered or 
enhanced function of the genes involved. They frequently affect tyrosine kinases 
or transcription factors (SK Bohlander, 2000; T Burmeister, 2000; U Krug, 2005;  
H Lodish, 2007; F Mitelman, 2007).  
However, the distinction between translocations resulting in fusion genes or in 
deregulated gene expression is sometimes not easy, since there are apparently 
genes that can be involved both in translocations leading to the formation of fusion 
genes and in translocation leading to the overexpression of breakpoint adjacent 
genes. One such gene is ETV6 (SK Bohlander, 2005).  
An example of overexpression of a gene as the driving force in tumorigenesis is, 
among others, CDX2 that is involved in the rare t(13;12) translocation. Even 
though an ETV6/CDX2 fusion transcript is produced, the main leukemogenic force 
is the overexpression of CDX2, which is also a result of this translocation  
(VPS Rawat et al., 2004). Subsequently it was shown that CDX2 is also 
overexpressed in AML and ALL cases without the t(12;13) (VPS Rawat et al., 
2008; S Thoene, 2008). In cell line experiments as well as in mouse models, 
Scholl et al. corroborated the theory of CDX2 as a driving force in leukemogenesis 
(C Scholl, 2007). 
Ectopic Expression of neighboring genes as a reason for leukemogenesis is also 
suspected in other translocations involving ETV6. For example, this is the case 
with the translocation t(1;12)(p36.1;p13), which was discovered in a patient with 
Myelodysplastic Syndrome (MDS). Here they hypothesized that altered expression 
of surrounding genes might be the MDS-inducing factor. Real-time PCR 
experiments showed that RPL11, a gene in close vicinity to MDS2, was expressed 
at higher levels in samples from patients with the t(1;12) than in normal bone 
marrow samples (MD Odero, 2002).  
Panagopoulos et al. investigated a rearrangement of the 12p13 region in a case of 
pediatric pre-B ALL. The rearrangement involved ETV6 and BAZ2A. The chimeric 
protein is also very short in length and very similar to the ETV6/STL and 
ETV6/MDS2 fusions. So the ETV6/BAZ2A fusion was not expected to have any 
function. They rather hypothesized that the pathogenic mechanism is the 
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deregulation of BAZ2A. They assume BAZ2A comes under the control of either a 
cryptic promoter or the promoter of ETV6 (I Panagopoulos, 2006).  
Cools et al. studied the translocations t(4;12)(q11-q12;p13) and t(5;12)(q31;p13). 
In both cases, no functional fusion gene of ETV6 could be identified. However they 
showed that the homeobox gene GSH2 (4q11-q12) and the growth factor gene IL3 
(5q31) were ectopically expressed in these two cases, suggesting that these 
events might be the drivers of leukemogenesis (J Cools, 1999 and 2002). 
The translocation t(6;12)(q23;p13) causes the generation of fusion genes of ETV6 
and STL. As in the cases of CDX2, MDS2, BAZ2A and GSH2 that are described 
above, the leukemic effects of the translocation are not fully understood. Neither 
the STL/ETV6 fusion nor the reciprocal ETV6/STL fusion shows a long open 
reading frame (ORF) (see Figure 4.2). The resulting fusion protein is, like the other 
examples, very small and lacks any known functional domain. No homologies to 
other known proteins could be observed (Y Suto, 1997). Therefore, as with the 
other examples, they assumed dysregulation of another nearby gene as a 
leukemogenic effect.  
 
 
Figure 4.2: Here the ETV6, the ETV6/STL and the STL/ETV6 protein structure are shown. Adapted from  
Y Suto et al., 1997. 
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Figure 4.3: This figure depicts a map of the STL/OSTL loci. It displays the close relation between OSTL and 
STL. STL exons are demonstrated by light grey bars; OSTL exons by dark grey bars. Black arrows indicate 
the direction of transcription. Black bars at the bottom of the figure represent the genomic sequence. Adapted 
from L Fontanari Krause, 2006. 
 
In the case of t(6;12)(q23;p13), OSTL came into the focus of interest because it is 
located in the proximate vicinity of STL. OSTL even shares the first exon with 
STL. Figure 4.3 shows a map of the STL/OSTL loci to demonstrate the close 
relationship between the two genes. 
Furthermore, it seems that STL and OSTL are co-expressed. Therefore, we 
performed an expression analysis of OSTL in various leukemia samples. Our 
studies showed a higher expression of OSTL in patients with AML and especially 
with CML. This was quite surprising, because up to that time OSTL had been 
thought to be more important in the lymphatic cell lineage. It is expressed during 
B-cell development and the t(6;12)(q23;p13) was first described in a pediatric case 
of B-cell precursor ALL (L Fontanari Krause, 2006; Y Suto, 1997; LQ Zhang, 
1993). Therefore, our findings of the highest expression levels of OSTL in myeloid 
leukemia (especially CML) were interesting findings.  
Due to these findings, we have to conclude that OSTL is also involved in the 
leukemogenesis or the progression of these diseases. However, the molecular 
mechanisms of how OSTL contributes to myeloid neoplasm are not known at 
present. The detailed studies of L Fontanari Krause give some insights into the 
function of OSTL and thus provide a basis for forming some hypotheses about the 
role of OSTL in tumorigenesis. 
For example, Fontanari Krause et al. found that OSTL is also expressed during 
embryogenesis. This could mean that OSTL is involved in cell growth. In most 
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adult tissues the expression levels of OSTL are rather low. Therefore higher 
expression of OSTL in adult or leukemic cells might be an indicator that the normal 
cell physiology is disturbed. Alternatively, elevated expression of OSTL itself could 
be the reason for a disturbed cellular growth. This may also affect cell 
differentiation, proliferation or self-renewal, which are very sensitive processes in 
the cell regulation. Disturbance of these functions often results in malignant 
transformation (JK Warner, 2004; JA Kennedy, 2008). OSTL is thought to be 
involved in cell survival, which is also one of the processes that are frequently 
disturbed in malignant cells. For example, overexpression of CDX2 is assumed to 
enhance the self-renewal capacity (C Scholl, 2007).  
Also the interaction partners of OSTL bear the potential to mediate leukemogenic 
effects. These proteins have been shown to be HAX1 and SIVA (L Fontanari 
Krause, 2006).  
HAX-1 (HS1 associated protein X-1) can be found in almost all tissues, suggesting 
a fundamental role in the cell. It is mainly localized in the mitochondria and has 
been associated with signal transduction as well as regulation of the actin 
cytoskeleton. It is believed that HAX-1 has anti-apoptotic properties and that it 
promotes cell survival (Y Suzuki, 1997; A Mirmohammadsadegh, 2003). Han et al. 
discovered that HAX-1 inhibits the processing of caspase 9 and thus prevents 
apoptosis in cardiomyocytes. This supports the hypothesis that HAX-1 has anti-
apoptotic qualities (Y Han, 2006; J Shaw, 2009). Recently it was shown that  
HAX-1 is mutated in recessive severe congenital neutropenia (SCN; Kostmann 
disease). Klein et al. detected homozygous mutations in the HAX-1 gene in 
several patients with SCN. It has been proposed that the lack of HAX-1 causes 
increased apoptosis in myeloid progenitor cells and that this could be a potential 
mechanism for neutropenia in patients with SCN (AA Schäffer, 2009; C Klein, 
2006). 
The second OSTL interactor that is of great interest is SIVA. Prasad et al. first 
described SIVA in 1997. SIVA (named after Shiva, the Hindu God of destruction) 
plays an important role in death vs. life decisions in the cell. SIVA interacts with 
various members of the tumor necrosis factor (TNF) receptor family (e.g. CD27, 
GITR, OX40 and 4-1BB) and shows pro-apoptotic properties (KV Prasad, 1997). 
Okuno et al. found that SIVA is upregulated in colorectal tumors (K Okuno, 2001). 
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Later it was shown that SIVA is an effector of p53 in apoptosis and that it is 
involved in the induction of apoptosis after the DNA is damaged (JL Barkinge, 
2009). An isoform of SIVA, SIVA-1, also has negative regulatory potential on  
NF-κB and it is part of the T-cell receptor induced cell death (AICD, activation-
induced cell death) (R Gudi, 2006).  
The work of Fontanari Krause et al. shows that OSTL interacts both with HAX-1 
and SIVA and might thus influence apoptosis and cell survival. Maybe the 
deregulation disturbs the pathways of HAX-1 and SIVA and in this way alters the 
normal regulation of apoptosis and cell survival. This hypothesis is depicted 
graphically in Figure 4.4. To understand the underlying mechanism, a more 
detailed characterization of the interaction between OSTL and HAX-1 and SIVA is 
required.  
 
 
Figure 4.4: Fontanari Krause et al. worked out an interaction of OSTL with HAX-1 and SIVA. This figure 
demonstrates a potential mechanism of how the protein could relate in the cell. Adapted from L Fontanari 
Krause, 2006. 
 
4.3 Discussion of the methods 
4.3.1 Microarray analysis 
Microarray analysis has been used since 1995 to analyze the expression levels of 
genes (M Schena, 1995). Using this method, a large number of genes or even all 
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genes can be assayed simultaneously. This allows an overview of the expression 
pattern of groups of genes or all genes in a given condition (R van Haaften, 2006). 
A disadvantage of this method is the high amounts of RNA that are needed per 
experiment. 20-200 µg RNA were necessary for one of the earlier microarray 
experiments and even now at least 100 ng of RNA are required per chip, whereas 
for real-time PCR, only a few nanograms of RNA are needed (V Nygaard, 2003). 
In addition, both sensitivity and specificity are higher for real-time PCR in 
comparison to microarray analysis (Y Chen, 2009). 
Our initial microarray analysis included 129 patients with various types of leukemia 
and 10 samples with normal bone marrow. These data allowed us to determine a 
first rough trend of the expression levels of OSTL in leukemia. We used this 
analysis to get an overview of what we should expect in real-time PCR.  
 
4.3.2 Real-time PCR (quantitative PCR) 
The innovation of real-time PCR compared to traditional PCR is that the target 
sequence is not only amplified but also quantified during amplification. Real-time 
PCR is based on the principles of traditional PCR, but in real-time PCR the 
amplification of the DNA target can be observed in real-time. This has the 
advantage that the data are collected during the exponential phase of the 
amplification. This is the phase with the highest efficiency of the reaction and 
therefore offers the highest accuracy. And the exponential phase is not affected as 
much by confounding variables as the plateau phase. Thus the most reliable 
results can be obtained in the exponential phase (MT Dorak, 2006). 
Even very small amounts of DNA can be detected and quantified reliably. The 
real-time PCR system requires 1000-fold less RNA than conventional methods 
and still less than microarray experiments. Thus very subtle changes in the 
expression levels of a given gene can be detected (MT Dorak, 2006). 
 
4.3.2.1 SYBR Green versus TaqMan 
There are basically two detection systems in real-time PCR. One is the SYBR 
Green system, which uses an intercalating dye that emits a different fluorescence, 
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when it intercalates in any double-stranded DNA (dsDNA). The other system is 
named TaqMan and utilizes specific probes. 
In the SYBR Green system, the SYBR Green I fluorescent marker intercalates in 
all dsDNA. When intercalated, SYBR Green I emits fluorescence at a specific 
wavelength. The fluorescence intensity corresponds to the amount of dsDNA but 
is not specific for a target sequence. Because the SYBR Green I dye is not 
sequence-specific, assays with SYBR Green I require extensive optimization and 
post-processing (V van der Velden, 2003). The non-specific products could 
interfere with the results. The results would appear incorrectly high, as the non-
specific products would also be detected as dsDNA in addition to the sequence of 
interest. Furthermore, a melting curve analysis is required as post-processing to 
verify the results. With melting curve analysis, it is possible to distinguish between 
specific and non-specific PCR products (KM Ririe, 1997). 
The optimization of the PCR protocol for the SYBR Green system for the analysis 
of OSTL transcript levels turned out to be rather difficult. Primer dimers appeared 
despite all attempts to optimize the reaction. This system also had the risk of false 
results and we decided against this system and looked for a sequence-specific 
system. 
Another system is the TaqMan system. This system uses hydrolysis probes. 
Hydrolysis probes are oligonucleotide sequences that bind DNA specifically at the 
area of interest between the primers. A quencher fluorochrome is conjugated to 
one end of the probe and a reporter fluorochrome to the other end. The quencher 
fluorochrome absorbs the fluorescence emitted by the reporter dye as long as both 
are bound in close proximity to each other. This is because of the FRET effect 
(Förster (or fluorescence) resonance energy transfer) (D Grinzinger, 2002). The 
Thermus aquaticus (Taq) polymerase hydrolyzes the probe with its 5’ → 3’ 
exonuclease activity during the elongation step of the PCR cycles. Thereby the 
quencher and the reporter are separated. This way the FRET effect is lost and the 
reporter emits fluorescence of a specific wavelength. The emitted fluorescence 
rises proportionally to the increasing amount of target DNA in the reaction. 
Interference by non-specific amplification products does not occur (V van der 
Velden, 2003).  A schematic representation of both systems is depicted in Figure 
4.5. 
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The TaqMan system is more specific in comparison to the SYBR Green system 
and it does not require as much optimization or any post-processing. These facts 
made us decide in favor of the TaqMan system. 
 
 
Figure 4.5: This figure demonstrates the principle mechanisms of the SYBR Green dye and the hydrolysis 
probes, which are used in the TaqMan system. 
a) SYBR Green I system. During the elongation phase of the PCR cycle, SYBR Green I dye will bind to 
dsDNA. If SYBR Green I dye binds the PCR products, fluorescence will be emitted. With each cycle more 
PCR products will accumulate and with this the detected fluorescence will increase. 
b) Hydrolysis probes (TaqMan). The hydrolysis probe holds a quencher fluorochrome on one end and a 
reporter fluorochrome on the other end. In this close proximity, the quencher absorbs the fluorescence emitted 
by the reporter. During the elongation phase of the PCR cycle, the hydrolysis probe will be hydrolyzed by the 
Taq polymerase. This process separates the quencher from the reporter and the fluorescence emitted by the 
reporter becomes detectable. With each additional PCR cycle, more hydrolysis probes become hydrolyzed as 
more PCR products are generated. In this way, the fluorescence increases proportionally to the amount of the 
PCR products. Adapted from V van der Velden, 2003. 
 
 79 
4.3.2.2 Basics of real-time PCR evaluation 
Ct-values (cycle threshold) 
The high accuracy of the real-time PCR is due to the fact that the data are 
collected during the exponential phase of amplification. This is the phase that is 
the least susceptible to confounding factors (SM McChlery, 2003). The most 
important parameter for the evaluation of the data is the threshold cycle. The 
threshold is a certain fluorescence level, arbitrarily set well above the background 
fluorescence. The threshold cycle or Ct-value is the cycle when the fluorescence 
rises above this threshold for the first time.  
The Ct-value allows for the comparison of different samples used in one 
experiment. The higher the initial amount of target DNA, the sooner the 
fluorescence rises above the threshold. It follows that a small Ct-value 
corresponds to a higher amount of target sequence in the original cDNA sample 
and therefore for a higher expression of the gene of interest.  
 
 
Figure 4.6: This figure displays an example of an amplification plot of a real-time PCR experiment. This 
hypothetical graph demonstrates important nomenclature for real-time PCR. The plot is achieved by plotting 
the fluorescence signal versus the PCR cycle number. The baseline describes the range in which the 
amplification cannot be differentiated from the background fluorescence. The threshold is a line above the 
background. Fluorescence rising above the threshold is considered as significant and can be used to 
determine the threshold cycle. The Ct-value is the cycle number in which the plot crosses the threshold. The 
ΔCt-value can be calculated by subtracting the Ct-value of one sample from the Ct-value of another sample. A 
solid line and a dotted line illustrate two different samples. The Ct-value of the solid line is 18, as the line 
crosses the threshold in this cycle. The Ct -value of the dotted line is 20. Subtracting one from the other, the 
ΔCt-value is 2 in this hypothetical case. Adapted from DG Grinzinger, 2002. 
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Calculation of the efficiency 
It is recommended that the efficiency of the PCR amplification is determined 
before starting the actual experiments (MT Dorak, 2006). Therefore we performed 
a standard curve analysis. For this, a series of dilutions in 10-fold steps was 
prepared. Then the Ct-values were plotted against the logarithm of the template 
concentration. The slope derived from this graph should ideally be about -3.32. 
This would mean that every target sequence doubles in every cycle. The efficiency 
(Ex) can be calculated with the slope of the standard curve experiment and 
Equation 4.1.  
 
Equation 4.1: This equation was used for calculating the efficiency of the primer/probe sets. Ex represents 
efficiency. The slope is derived from standard curve experiments (MT Dorak, 2006). 
We evaluated the efficiency of our PCR on plasmids as well as cDNA of the cell 
line SEM. The trials with plasmids mostly showed better results than with the cell 
line. For example, we calculated the efficiency for the primer/probe set 
OSTL783/883. The experiment with plasmids reached an efficiency of 99%, 
whereas the experiment using cDNA from the cell line only reached  
80% efficiency. The difference in the efficiency could be due to the difference in 
the amount of target sequence and due to the presence of other transcripts in the 
cDNA from the SEM cell line. We know that OSTL is not expressed in abundance. 
This becomes apparent in the Ct-value range of the experiments. The experiments 
with plasmids showed lower Ct-values although we used very high dilutions to 
ensure a better comparability. But still the plasmid experiment reached Ct-values 
between 20 and 31, probably due to a greater concentration of the target 
sequence, whereas the Ct-values of the cell line experiment were in the range of 
29 to 37. It is known that the real-time PCR is not as reliable in the higher Ct-value 
range compared to the lower (MT Dorak, 2006). This could explain the 
discrepancy between the experiments with the cell line and the plasmids even 
though the same primer and probe sets were used. And it could be an element of 
uncertainty in our analysis. 
The efficiency varied greatly between different primer/probe sets, although they 
were all designed using the same standards and most of them reached the same 
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score in the Primer Express Software. We chose the set with the best efficiency for 
our experiments, to ensure the best conditions possible. The primer pair 
OSTL783/883 gave the best results with 99% efficiency in the plasmid standard 
curve experiment and 80% in the cell line experiment, whereas OSTL861/961 
scored slightly inferiorly with 95% and 65%, respectively. OSTL574/647 only 
reached 39.62% in the plasmid experiment and was excluded. OSTL436/536 
showed the worst results with no consistent amplification. 
 
Normalization 
To generate valid and objective results, the data obtained from the real-time PCR 
experiments need to be normalized to so-called control genes. Usually 
housekeeping genes will be used as endogenous control genes (J Vandesompele, 
2002). It is assumed that housekeeping genes are expressed at constant levels in 
different cell types and throughout the cell cycle.  
The internal control system functions as an active reference and is used to 
compensate for differences in the initial amount of cDNA. Therefore the Ct-value of 
the control gene is subtracted from the Ct-value of the gene of interest. This 
results in the ΔCt-value.  
However, there is no guarantee that the housekeeping genes that are expressed 
at constant levels in healthy cells are also expressed the same way in malignant 
cells. We evaluated three housekeeping genes: TBP, GUSB and β-Actin. We 
chose β-Actin for our experiments, because it showed the most reliable results and 
Dorak et al. recommend β-Actin for normalization (MT Dorak, 2006).  
 
Comparative Ct-method (ΔΔCt-method) 
The comparative Ct-method is used for the relative quantification of the template 
DNA when the expression level of a given gene should be compared between two 
samples or two groups of samples. The method is based on the ΔCt-value (see 
previous chapter). One group of samples is set as baseline or reference. To 
achieve the ΔΔCt-value, the ΔCt-value of the reference will be subtracted from 
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every sample that it should be compared to. The ΔΔCt-values may be positive or 
negative (MT Dorak, 2006). 
Equation 4.2 can be used to calculate how much the samples differ in expression. 
 
Fold change = 2ΔΔCt 
Equation 4.2: With this equation the fold change between two expression levels can be calculated. ΔΔCt is the 
difference between the two ΔCt-values of the two compared values. The equation is based on the assumption 
that every PCR amplicon doubles in every PCR cycle. 
 
It is assumed that the efficiency is 100%. The standard curve analysis with 
plasmids showed an efficiency of almost 100%. But this is a rather artificial 
situation, because in this scenario each plasmid holds the target sequence. The 
standard curve analysis with the cell line SEM gives a better reflection of the real 
conditions. Here the efficiency only reached 80%. To take this into account in the 
calculation, Equation 4.2 needs to be corrected (MW Pfaffl, 2001). This is shown in 
Equation 4.3. In this way, Equation 4.3 provides more accurate results, which are 
adapted to the real conditions of the reaction. 
 
Fold change = 1.8ΔΔCt 
Equation 4.3: The equation is based on Equation 4.2. It considers the efficiency of 80% of primer/probe set 
OSTL783/883. 
 
4.4 Conclusion 
For this study we used two different methods to analyze the expression profile of 
OSTL. One of the methods, the microarray analysis, has the advantage that it 
covers a greater collective of patients, as well as a greater variety of leukemia 
types and even normal bone marrow samples. The other method, the real-time 
PCR, did not include that many patients but, nevertheless, it is known for its 
greater specificity and sensitivity. 
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Despite the methodological differences, the results show the same trend. OSTL is 
expressed higher in CML patients than in other leukemia patients. Additionally the 
real-time PCR revealed that the expression levels of OSTL in the AML cohort do 
not differ much from the CML patients. This means myeloid leukemia shows the 
highest expression of OSTL. These results were very surprising, because previous 
experiments indicated that OSTL is important for the lymphatic cell lineage.  
A hypothesis about how OSTL is involved in the development of leukemia is that, 
because of the dysregulation of OSTL, the normal function of HAX-1 or SIVA, or 
both, are disturbed. This would lead to a disturbance of apoptosis and in this way 
could contribute to leukemogenesis.  
We aimed to gain more information on OSTL. Especially we wanted to find a 
connection between OSTL and a leukemia subtype and this way to contribute to 
the general understanding of OSTL in leukemogenesis. The new knowledge of 
OSTL and its potential role in myeloid leukemia may help to establish further 
experiments that will ultimately have an implication on diagnosis, therapy or 
prognosis of the patients with CML or AML. For instance it would be interesting to 
perform a knock-down of OSTL in CML cell lines and validate the importance of 
OSTL overexpression for the survival of these cells. 
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5. Summary 
ETV6 is a gene that is known to be involved in translocations, especially in the 
context of Leukemia. For these translocations several leukemogenic mechanisms 
have been described. One mechanism is the aberrant or ectopic expression of a 
neighboring gene. In this way, the focus of interest was directed towards the OSTL 
gene. It is located in direct proximity to the translocation t(6;12)(q23;p13). This 
translocation involves the ETV6 gene, as well as a previously unknown gene 
(named STL) and, contrary to expectations, does not produce any functional 
fusion gene. Therefore L Fontanari Krause analyzed the OSTL gene in detail to 
learn about the leukemogenic potential of this gene, in particular in the context of 
this translocation. 
OSTL is expressed in many different tissues during the embryogenesis of mice, as 
well as during B-cell development. OSTL protein is highly conserved and little 
discrepancy can be detected in the protein structure in comparison to the protein 
in mice. The protein structure of OSTL shows a RING-IBR-RING or TRIAD motive, 
which is usually found in ubiquitin ligases. Fontanari Krause et al. could not verify 
this function for the OSTL protein. But they could show an interaction of OSTL with 
the proteins HAX-1 und SIVA. Both proteins are known to be involved in the 
regulation of apoptosis. 
However, there are still many questions about the concrete function of OSTL in the 
cell as well as its task in leukemogenesis. With this study, we want to approach 
the question of how OSTL could be involved in tumorigenesis. To date it is 
assumed that the leukemogenic effect of translocations involving ETV6 is either 
due to a fusion gene with altered or enhanced function, or to a neighboring gene, 
which is affected in the way that its expression is changed. In the case of the 
t(6;12)(q23;p13), no functional fusion gene was found. Therefore we assume that 
overexpression of OSTL is the crucial leukemic effect.  
In this study we wanted to find a link of OSTL to a certain subgroup of leukemia. 
To validate our hypothesis, we used two methods to analyze gene expression. 
One method (the microarray analysis) provides an overview of the expression 
levels of many genes in large cohorts of patients. But no precise data of the 
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expression levels are available with the microarray analysis. To measure the 
accurate expression levels, we used real-time PCR. 
The microarray analysis of 129 patients showed that OSTL is expressed 
approximately twice as high in patients with CML compared to patients with AML, 
ALL or healthy individuals.  
The real-time PCR experiments (39 patients) confirmed the trend in terms of the 
CML and the ALL cohort. But it appeared that OSTL in AML patients is expressed 
almost equally to the patients with CML. These results show that the expression of 
OSTL is higher in both myeloid leukemias, which is in contrast to our anticipation. 
Furthermore, we could demonstrate that OSTL is expressed five times lower in 
ALL patients than in the patients with myeloid leukemia. The ALL cohort is very 
heterogeneous and we could show that in the ALL-Ph+ subgroup, OSTL is 
expressed nine times lower than in the CML patients, whereas in the T-ALL group 
it is expressed only 1.5 times lower. 
In summary, our results demonstrate that overexpression of OSTL is rather linked 
to myeloid leukemia and not, as expected, to lymphoid leukemia. These results 
provide novel information that might be the basis for experiments that answer 
questions concerning the leukemogenic effect of OSTL. 
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6. Zusammenfassung 
In der aktuellen Forschung wird Translokationen ein immer höherer Stellenwert in 
der Entstehung von Leukämien zugemessen. Das Gen ETV6 wurde als häufiger 
Translokationspartner identifiziert und verschiedene leukämogene Mechanismen 
dieser Translokationen sind bisher beschrieben worden. Einer dieser 
Mechanismen beinhaltet, dass es durch die Translokation zu einer ektopen oder 
aberranten Expression von benachbarten Genen kommt. So ist man auf das Gen 
OSTL aufmerksam geworden. Es liegt in der unmittelbaren Nähe der 
Translokation t(6;12)(q23;p13), welche das Gen ETV6 sowie ein zuvor 
unbekanntes Gen (STL) betrifft und zu keinem funktionsfähigen Fusionsgen führt. 
Fontanari Krause et al. haben daraufhin das Gen OSTL eingehend charakterisiert. 
Das Gen OSTL wird während der Embryogenese der Maus in vielen Geweben 
sowie während der B-Zell-Entwicklung exprimiert. OSTL ist hoch konserviert und 
es wurden nur geringe Abweichungen in der Protein-Struktur im Vergleich zum 
Maus-Protein gefunden. Auf Proteinebene zeigte sich ein RING-IBR-RING 
beziehungsweise ein TRIAD-Motiv, welches normalerweise für Ubiquitinligasen 
typisch ist. Diese Funktion konnte bei dem Protein OSTL nicht nachgewiesen 
werden. Allerdings zeigten Experimente eine Interaktion mit den Proteinen HAX-1 
und SIVA, die beide in die Regulation von Apoptosen involviert sind. 
Es sind jedoch noch viele Fragen hinsichtlich der genauen Funktion von OSTL in 
der Zelle und bezüglich des Einflusses auf die Leukämieentstehung offen. Bisher 
wird angenommen, dass es sich bei dem leukämogenen Effekt von 
Translokationen mit ETV6 entweder um ein Fusionsgen mit veränderter 
beziehungsweise verstärkter Funktion handelt oder um ein benachbartes Gen, das 
durch die Translokation sein Expressionsverhalten ändert. Da im Fall der 
t(6;12)(q23;p13) kein funktionsfähiges Fusionsgen gefunden wurde, gehen wir 
davon aus, dass es sich hier um den anderen Mechanismus handeln muss. 
Um diese Hypothese zu bestätigen haben wir uns zweier Methoden zur Analyse 
von Genexpression bedient. Die Microarray-Methode gibt einen Überblick über die 
Expression einer Vielzahl von Genen und hat in diesem Fall den Vorteil, dass mit 
dieser Methode  ein größeres Patientenkollektiv erfasst wurde. Die Microarray-
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Analyse gibt aber keine genauen Angaben über die Expressionshöhe. Um jedoch 
auch die exakten Expressionslevel von OSTL zu erfahren, haben wir zusätzlich  
real-time PCR-Experimente durchgeführt. 
Dabei haben wir eine erhöhte Expression von OSTL in der Gruppe der Patienten 
mit ALL erwartet, da die Translokation bei einem Patienten mit B-Zell ALL entdeckt 
wurde und da OSTL in vorangegangenen Experimenten eher mit dem 
lymphatischen System in Verbindung gebracht wurde. 
Mit dieser Arbeit wollten wir eine Verbindung von OSTL zu einer Untergruppe der 
Leukämien finden. 
In der Microarray-Analyse von 129 Patienten zeigte sich, dass OSTL ungefähr 
doppelt so hoch bei Patienten mit CML exprimiert wird wie bei Patienten mit AML, 
ALL oder nicht erkrankten Patienten. 
Die real-time PCR-Experimente (39 Patienten) haben den gleichen Trend gezeigt 
wie die Microarray-Analyse. CML zeigt auch hier die höchste Expression. Es 
stellte sich jedoch heraus, dass OSTL bei AML Patienten nahezu gleich wie bei 
CML Patienten exprimiert wird. Dies bedeutet, dass OSTL am höchsten in den 
myeloischen Leukämien exprimiert wird. Diese Ergebnisse weichen von der 
Ausgangshypothese ab. 
Außerdem konnte gezeigt werden, dass die Expression von OSTL bei ALL 
Patienten fast fünffach geringer ausgeprägt ist gegenüber den Patienten mit 
myeloischen Leukämien. Allerdings variiert das Expressionsverhalten unter den 
ALL-Subgruppen erheblich, genauer zwischen einer neunfach geringeren 
Expression im Vergleich zu den myeloischen Leukämien in der ALL-Ph+ Gruppe 
und einer nur 1,5-fach geringeren Expression in der T-ALL Kohorte. 
Zusammenfassend handelt es sich um überraschende Ergebnisse, die OSTL- 
Überexpression mit myeloischen und nicht wie erwartet mit lymphatischen 
Leukämien in Verbindung bringen. Diese neuen Informationen über OSTL stellen 
eine Grundlage für weitere Experimente dar, welche zum Verständnis der 
Entstehung von Leukämien beitragen können. 
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Appendix: Table with patient details 
1 CML 72 46,XX,t(9;22)(q34;q11) [24] 46,XX [1] 
BCR-ABL- fusion 
transcript type b2a2 
2 CML 51 46,XY,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b3a2 
3 CML 63 46,XY,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b2a2 
4 CML 44 46,XX,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b2a2 
5 CML 59 46,XX,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b3a2 
6 CML 73 46,XY,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b3a2 
7 CML 61 46,XX,t(9;22)(q34;q11) [25] 
BCR-ABL- fusion 
transcript type 
b3b2a2 
8 CML 35 46,XY,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b3a2 
9 CML 47 46,XX,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b3a2 
10 CML 64 46,XY,t(9;22)(q34;q11) [25] BCR-ABL- fusion transcript type b2a2 
11 ALL; Ph pos 66 
46,XY,t(9;22)(q34;q11),del(9)(p22) 
[10] 
46,XY [13] 
BCR-ABL- fusion 
transcript 
12 ALL; Ph pos 62 
46,XX,der(9)t(9;22)(q34;q11)del(9) 
(p13),der(19)t(8;19)(q13;p13),der(2
2), t(9;22)(q34;q11) [13] 
46,XX [5] 
BCR-ABL- fusion 
transcript 
13 ALL; Ph pos 74 
47,XY,t(2;16)(p11;p11),+8, 
t(9;22)(q34;q11) [14] 
46,XY [6] 
BCR-ABL- fusion 
transcript type e1a3 
No Type of Leukemia 
Age at 
diagnosis Karyotype 
Molecular 
Marker 
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14 ALL; Ph pos 39 
45,XY,der(7;9)(q10;q10), 
t(9;22)(q34;q11) [6] 
46,XY [16] 
BCR-ABL-fusion 
transcript type b2a2 
15 ALL; Ph pos 39 
45,XY,-9,t(9;22)(q34;q11)[3] 
46,XY,idem,+der(22)t(9;22)(q34;q1
1) [22] 
BCR-ABL-fusion 
transcript type; 
second time no 
detection 
16 ALL; t4;11pos 37 
46,XY,t(4;11)(q21;q23) [17] 
46,XY [3] 
MLL-AF4 pos 
FLT3D324- 
FLT3V592- 
17 ALL; t4;11pos 61 46,XX,t(4;11)(q21;q23) [5] FLT3-LM- MLL-AF4+ 
18 ALL; t4;11pos 71 
46,XX,t(4;11)(q21;q23)[14] 
46,XX [3] MLL-AF4+ 
19 ALL; t4;11pos 25 
46,XX,t(4;11)(q21;q23)[18] 
46,XX [1] MLL-AF4+ 
20 ALL; t4;11pos 68 46,XX,t(4;11)(q21;q23)[4] MLL-AF4+ FLT3-LM- 
21 common ALL 37 
81-86,XX,-X,-X,del(1)(p32),-2, 
-4,+5,t(5;11)(?;?),-6,-7,+8,-10,-11,-
12,-15,-17 [cp5] 
46,XX [13] 
FLT3D324- 
22 common ALL 21 
46-47,XX, 
del(6)(q15),der(8)t(8;15)(p11;q11), 
ins(12;21)(p13;q22q22),-15,+16 
[cp10] 
 
23 common ALL 72 47,XX,+X [1] 47,XX,+X,i(8)(q10)[1],46,XX [18] FLT3-LM- 
24 common ALL 79 
62-64,XXY,+Y,-2,-3,+6,-7,+8,-
9,+11,+12, -13,-
15,der(15;18)(q10;q10),-16,-17, 
-18,+19,der(19)t(6;19)(q11;p13) 
[cp6] 
46,XY [14] 
 
25 common ALL 77 46,XX,t(X;14)(p22.3;q32) [10] 46,XX [10]  
26 T-ALL 19 46,XX,del(7)(q22) [12] 46,XX [9]  
27 T-ALL 59 
4-
45,XX,der(1)t(1;18),del(3)(p?),del(
4) 
(q11),der(5)t(4;5)(?;q11),del(9)(q11
), 
del(11)(q11),der(13)t(11;13)t(11;16
), 
der(19)t(1;19)t(1;4),der(21)t(16;21) 
[cp11] 
88-90,idemx2 [cp2] 
46,XX [2] 
NPM1- FLT3-LM- 
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28 T-ALL 33 48,XY,+8,del(9)(p13p22),+10 [9] 46,XY [10] FLT3-LM- NPM1- 
29 T-ALL 64 
46,XY,der(2;17)(p11;q11),del(7)(q1
1.2), 
der(16)t(7;16)(?;q22)t(2;7)(p11;?),d
er(17)del(17)(p11)del(17)(q12) [14] 
46,XY [1] 
 
30 T-ALL n/a 
46,XY,del(9)(p?13p?23), 
+del(9)(p?13p?23),der(10;21)(q10;
q10) [8] 
46,XY [6] 
 
31 AML norm karyotype 21 46,XY NPM1+ FLT3-LM- 
32 AML norm karyotype 37 46,XY 
FLT3-LM- NPM1+  
NRAS codon 12+ 
33 AML norm karyotype 68 46,XY FLT3- NPM1- 
34 AML norm karyotype 42 46,XX 
FLT3+ FLT3-LM+ 
NPM1+ 
35 AML norm karyotype 63 46,XY FLT3- NPM1+ 
36 AML norm karyotype 66 46,XX 
FLT3-LM- NPM1- 
CEBPA+ 
37 AML norm karyotype 72 46,XX FLT3-LM- NPM1- 
38 AML norm karyotype 63 46,XX 
FLT3-LM- NPM1+ 
FLT3D835+ 
39 AML norm karyotype 70 46,XY FLT3-LM+ NPM1- 
40 AML norm karyotype 79 46,XX 
RNA FLT3-LM-  
NPM1+ 
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Abbreviations 
 
 
°C Degree Celsius 
AA = aa Amino acids 
AICD Activation-induced cell death 
ALL Acute Lymphoid/Lymphoblastic Leukemia  
AML Acute Myeloid/Myelogenous Leukemia 
Aqua bidest. Water double deionized filtered trough Millipore filters 
BLAST  Basic Local Alignment Search Tool 
BM Bone Marrow 
B-NHL  B-cell-Non-Hodgkin-Lymphoma 
bp Base pair(s) 
C  Cytosine 
cDNA Complementary DNA, synthetic DNA transcribed from a 
specific RNA through the action of the reverse transcriptase 
CML Chronic Myeloid/Myelogenous Leukemia 
Ct Threshold cycle 
ΔCt  Ct-value normalized with the Ct-value of a housekeeping 
gene 
ΔΔCt Difference between 2 ΔCt-values of interest 
del Deletion 
DEPC Diethyl pyrocarbonate 
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DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
DNase  Desoxyribonuklease  
DRIL Double RING finger linked 
dNTP Deoxynucleotidetriphosphate 
dsDNA Double-stranded DNA  
DSMZ German Collection of Microorganisms and Cell Cultures 
DTT Dithiothreitol 
EBV  Epstein–Barr virus 
EDTA Ethylenediaminetetraacetic acid 
Ex Efficiency of the real time PCR reaction 
FAB French-American-British Classification 
FCS  Fetal calf serum 
FISH Fluorescence-in-situ-hybridization   
FRET  Förster (fluorescence) resonance energy transfer 
FW Forward 
g Gram 
G  Guanine 
HLH  Helix loop helix 
HSC Hematopoietic stem cell  
IBR In between RING fingers 
Ig Immunoglobulin 
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IgH Immunoglobulin; heavy chain 
IgL  Immunoglobulin; light chain 
Inv 
IQR 
Inversion 
inter quantile range 
l Liter 
M Molar 
MDS Myelodysplastic Syndrome 
µg Microgram 
min Minute(s) 
mix Mixture 
ml Milliliter 
µl  Microliter 
mM Millimolar 
µM Micromolar 
mRNA Messenger RNA 
NaHCO3 Sodium bicarbonate 
NaOH  Sodium hydroxide 
ng Nanogram 
nk Normal karyotype 
nm Nanometer 
ORF Open reading frame 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
 105 
Pen/Strep Penicillin/Streptomycin 
pg Picogram 
Ph+ Philadelphia chromosome ( t(9;22)(q34;q11)) positiv 
pM Picomolar 
PTK Protein tyrosine kinases  
q-PCR real-time PCR (quantitative PCR) 
RING1 Really Interesting Protein 1 
RING2 Really Interesting Protein 2 
RNA Ribonucleic acid 
RNase Ribonuclease 
rpm  Revolutions per minute 
RPMI  Roswell Park Memorial Institute culture medium 
RQ Relative Quantification 
RT-PCR Reverse transcription PCR (cDNA synthesis) 
RV Reverse 
SAM  Sterile alpha motive 
SCN Severe Congenital Neutropenia  
sec Second 
t Threshold  
Taq Thermus aquaticus (-Polymerase) 
TBE TRIS-Borat-EDTA-Puffer 
TCR T-cell receptor  
TE Tris-EDTA buffer 
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TNF Tumor necrosis factor  
TRIAD Two RING fingers and DRIL 
TRIS Trishydroxyaminomethan 
U Unit 
UV Ultraviolet light 
V Volt 
VSN    Variance stabilization and calibration for microarray data 
WBC White blood cells 
WHO World Health Organization  
x g    Times gravity 
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